CA1341082C - Method of treating tumor cells by inhibiting growth factor receptor function - Google Patents

Method of treating tumor cells by inhibiting growth factor receptor function

Info

Publication number
CA1341082C
CA1341082C CA000588056A CA588056A CA1341082C CA 1341082 C CA1341082 C CA 1341082C CA 000588056 A CA000588056 A CA 000588056A CA 588056 A CA588056 A CA 588056A CA 1341082 C CA1341082 C CA 1341082C
Authority
CA
Canada
Prior art keywords
antibody
tumor cells
growth
cytotoxic
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000588056A
Other languages
French (fr)
Inventor
Robert M. Hudziak
H. Michael Shepard
Axel Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26841520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1341082(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of CA1341082C publication Critical patent/CA1341082C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.

Description

1 341 ~8 2 METHOD OF TREATING TUMOR CELLS
BY INHIBITING GROWTH FACTOR RECEPTOR FUNCTION
Field of the Invention This invention is in the fields of immunology and cancer diagnosis and therapy. More particularly it concerns antibodies specifically binding growth factor receptors, hybridomas that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use> of the antibodies alone or in combination with cytotoxic far.tor(sc) in therapeutic methods. Also encompassed by the invention is an assay for tyrosine kinases that are involved in tumorigenesis.
Background of the Invention Macrophages a.re: one of the effector cell types that play an important role in immunosurveillance against neoplastic growth in vivo. In vitro, cell-mediated cytotoxicity requires selective binding between a<:tivated macrophages and target cells as well as the concomitant release of cytotoxic factors. Some of the cytotoxic fs.ctors secreted by activated macrophages include reactive oxygen species such as the superoxide anion and hydrogen peroxide, ar~;inas~a, interleukin 1, and tumor necrosis factor-a (TNF-a). Acquired resistance to the toxic effects of these factors by tumor cells could be one mechanism which leads to the onset and spread of tum~~r formation in vivo.
The observation that TNF-a can act as a potent effector of the macrophage-mediated antitumor response provides a rationale for its use in further studies on the regulation of tumorigenesis in vivo and tumor cell growth in vitro. The genes encoding TNF-a and TNF-a structurally related cytotoxic protein formerly known as lymphotoxin, have been cloned and the corresponding proteins expressed in Esche.richia coli. These proteins display an array of biological activities, including induction of hemorrhagic necrosis ~34~ X82 of Meth A sarcomas in vivo, inhibition of the growth of certain tumor cells in v_~itro, synergistic enhancement of the in vitro anticellular effe~cta of IFN-7, activation of human polymor-phonuclear neutrophil functions, and inhibition of lipid biosynthesis. Recently, rHuTNF-a was shown to augment the growth of normal diploi<i fibroblasts in vitro. The divergent proliferative responses in the presence of rHuTNF-a are sometimes related to variations in TNF binding.
Growth factors and their receptors are involved in the regulation of cell proliferation and they also appear to play a key role in onco genesis. Of the known proto-oncogenes, three are related to a growth factor or a growth factor receptor. These genes include: c-s.is, which is homologous to the transforming gene of the simian. sarcoma virus and is the B chain of platelet-derived growth factor (PDGF); c-fms, which is homologous to the transforming gene of the feline sarcoma virus and is closely related to the macrophage colony-stimulating factor receptor (CSF-1R); an c-erbB, which encodes the EGF receptor (EGFR) and is homologous to~ the transforming gene of the avian erythroblastosis virus (v-erbB). The two receptor-related proto-oncogenes, c-fms and c-erbB, are members of the tyrosine-specific protein kinase family to which many proto-oncogenes belong.
Recently, a novel transforming gene was identified as a result of transfection ;studies with DNA from chemically induced rat neuroblastomas. This gene, called neu, was shown to be related to, but distinct from, the c-erbB proto-oncogene. By means of v-erbB
and human EGFR as probes to screen human genomic and complementary DNA (cDNA) libraries, two other groups independently isolated human erbB-related ,genes that they called HER2 and c-erbB-2 respectively.
Subsequent sequence analysis and chromosomal mapping studies revealed that c-erbB-2, and HER2 are species variants of neu. A
fourth group, also using v-erbB as a probe, identified the same ~ 34 ~ 08 2 gene in a maramary carcinoma cell line, MAC 117, where it was found to be amplified five- to ten-fold.
This gene, which will be referred to herein as HER2, encodes a new member of the i:yrosine kinase family; and is closely related to, but distinct from, the EGFR gene as reported by Coussens et al., Science 230, 1132 (1985). HER2 differs from EGFR in that it is found on t>and q21 of chromosome 17, as compared to band pll-p13 of chromosome: 7, where the EGFR gene is located. Also, the HER2 gene generates a messenger RNA (mRNA) of 4.8 kb, which differs from the 5.8- and 10-kb transcripts for the EGFR gene. Finally, the protein encoded by t:he HER2 gene is 185,000 daltons, as compared to the 170,000-dalton protein encoded by the EGFR gene. Conversely, on the basis of sequence data, HER2 is more closely related to the EGFR gene than to other members of the tyrosine kinase family.
Like the EGFR protein, the HER2 protein (p185) has an extracellular domain, a transmembrane domain that includes two cysteine-rich repeat clusters, and an intracellular kinase domain, indicating that it is likely to be a cellular receptor for an as yet unidentified ligand. HER2 p185 is referred to as p185 or the HER2 receptor herein.
Southern analysis of primary human tumors and established tumor-derived cell. :Lines revealed amplification and in some cases rearrangement of t:he EGF receptor gene. Amplification was particularly apparent in squamous carcinomas and glioblastomas.
The HER2 genE: was also found to be amplified in a human salivary gland adenoc.arcinoma, a renal adenocarcinoma, a mammary gland carcinoma, arid a gastric cancer cell line. Recently, Slamon et al., Science 235, 177 (1987) demonstrated that about 30$ of primary human breast carcinoma tumors contained an amplified HER2 gene.
Although a few sequence rearrangements were detected, in most tumors there were no obvious differences between amplified and normal HER2 genes. Furthermore, amplification of the HER2 gene correlated significantly with the negative prognosis of the disease and the probability of relapse.
To investigates the significance of the correlation between over-expression and cellular transformation as it has been observed for proto-on~:ogenes c-mos and N-myc, a HER2 expression vector and a selection scheme that permitted sequence amplification after transfection of mouse NIH 3T3 cells was employed by Hudziak et al., Proc. Natl. Acad. Sci. (USA) 84, 7159 (1987). Amplification of the unaltered HER2 gene in NIH 3T3 cells lead to over-expression of p185 as well as cellular transformation and tumor formation in athynic mice.
The effects of antibodies specifically binding growth factors or growth j=actor receptors has been studied. Examples are discussed be:Low.
Rosenthal et al., Cell 46, 301 (1986) introduced a human TGF-a cDNA expression vector into established non-transformed rat fibroblast cells. Synthesis and secretion of TGF-a by these cells resulted in loss of anchored-dependent growth and induced tumor formation in nude? mice. Anti-human TGF-a monoclonal antibodies prevented th~~ rat cells from forming colonies in soft agar, i.e.
loss of anchorage dependence. Gill et al., in J. Biol. Chem. 259 7755 (1984) disclose monoclonal antibodies specific for EGF
receptor which were inhibitors of EGF binding and antagonists of EGF-stimulated tyrosine protein kinase activity.
Drebin Eat al, in Cell 41 695 (1985) demonstrated that exposure of a neu-oncogene-transformed NIH 3T3 cell to monoclonal antibodies reactive with the r~eu gene product, cause the neu-transformed NIH
3T3 cell to oevert to a non-transformed phenotype as determined by anchorage independent growth. Drebin et al., in Proc. Natl. Acad.
Sci. 83, 9129 (1986) demonstrated that in vivo treatment with a monoclonal antibody (IgG2a isotype) specifically binding the '34~~8z _5_ protein encoded by the neu oncogene significantly inhibited the tumorigenic growth of neu-transformed NIH 3T3 cells implanted into nude mice.
Akiyama et al. in Science 232, 1644 (1986) raised antibodies against a synthetic peptide corresponding to 14 amino acid residues at the carbo~cy-ter_m:inus of the protein deduced from the c-erbB-2 (HER2) nucleotide sequence.
Growth factors have been reported to interact in both a synergistic and a.n antagonistic manner. For example, TGF-a and TGF-~ synergistical:ly enhance the growth of NRK-49F fibroblasts, whereas PDGF down regulates EGF receptor function on 3T3 cells. A
variety of transformed cells secrete factors which are believed to stimulate gr~~wth by an autocrine mechanism. Sugarman et al., Cancer Res. 47, 780 (1987) demonstrated that under certain conditions, ~;rowtta factors can block the antiproliferative effects of TNF-a on sensit:.ive tumor cells. Specifically, epidermal growth factor (EGF) and recombinant human transforming growth factor-a (rHuTGF-a) were shown to interfere with the in vitro antiproliferative effects of recombinant human tumor necrosis factor-a (rHuTNF-a) and -~ on a human cervical carcinoma cell line, ME-180. The inhibitory effect could be observed at EGF or rHuTGF-a concentrations of 0..1 to 100 ng/ml, and was maximal between 1 and 10 ng/ml. This reaponse was apparently not due to down regulation of the TNF receptor or to alteration of the affinity of TNF-a for its receptor. Since the antiproliferative effect of recombinant human interferon-7~ was not significantly affected by the presence of EGF or rHuTGF-a, the inhibition was specific for recombinant TNFs and was not due solely to enhanced proliferation induced by the growth i:actors. Neither growth factor had a substantial protective effect on the synergistic cytotoxicity observed when tumor cells were exposed simultaneously to rHuTNF-a and recombinant human inter:Eeron-7. TGF-~ can also interfere with the antiproliferative effects of rHuTNF-a in vitro. At concentrations ?34~ a82 of less than 1 ng/ml., TGF-~9 significantly antagonized the cytotoxic effects of rliuTNF~-a on NIH 3T3 fibroblasts. Since EGF, platelet-derived growth factor, and TGF-~ all enhanced NIH 3T3 cell proliferation, bu t only TGF-~ interfered with rHuTNF-a cytotoxicity, the protective effects of TGF-~ were not related in a simple manner to enhanced cell proliferation. rHuTGF-a and TGF-,B
did not have a significant protective effect against rHuTNF-a-mediated cytotoxicit:y on two other tumor cell lines, BT-20 and L-929 cells.
It is an object of the subject invention to provide antibodies capable of inhibiting growth factor receptor function.
It is a further object of the invention to provide an improved assay for the HER2 receptor.
It is a further object of the invention to provide improved methods of tumor therapy.
It is a further object of the invention to provide a method of inhibiting the growth of tumor cells which overexpress a growth factor receptor and/or growth factor.
It is a further object of the invention to provide a method for treating a 'tumor by treatment of the tumor cells with antibodies capable of inhibiting growth factor receptor function, and with cyto~~oxic factors such as tumor necrosis factor.
A still :Further object of the invention is to provide an assay for tyrosine lcinases that may have a role in tumorigenesis.
Other objects, features and characteristics of the present invention will become apparent upon consideration of the following description and the appended claims.

134~~82 _, _ Summary of the Invention The sut~~ect invention relates to monoclonal antibodies specifically binding, the external domain of the HER2 receptor. The invention also relates to an assay for the HER2 receptor comprising exposing cells to antibodies specifically binding the extracellular domain of the HER.? receptor, and determining the extent of binding of said ant:~bodies to said cells. Another embodiment of the invention relates to a method of inhibiting growth of tumor cells by administering to a patient a therapeutically effective amount of antibodies capable of inhibiting the HER2 receptor function. A
further embodiment of the invention relates to administering a therapeutica:'_ly effective amount of antibodies capable of inhibiting growth factor receptor function, and a therapeutically effective amount of a cytotoxic factor. A still further embodiment of the invention :is an assay for tyrosine kinases that may have a role in tumorigenesis comprising exposing cells suspected to be TNF-a resistant t:o TNF-a, isolating those cell which are TNF-a resistant, screening the isolated cells for increased tyrosine kinase activity, and isolating receptors and other proteins having increased tyrosine k.inase activity.
Brief Description of the Drawines Figure la shows TNF-a resistance of NIH 3T3 cells expressing various levels of HER2 p185. Figure lb shows macrophage cytotoxicity assays for NIH 3T3 cells expressing various levels of HER2 p185.
Figure 2 demonstrates the level of TNF-a binding for a control cell line (N:(H 3T3 neo/dhfr) and for a cell line overexpressing HER2 p185 (HE:(~2-3g00) .
Figure 3 shows inhibition of SK BR3 cell growth by anti-HER2 monoclonal antibodies.

Figure ~+ is a dose response curve comparing the effect of an irrelevant monoclonal antibody (anti-HBV) and the effect of monoclonal antibo<iy 4D5 (anti-HER2) on the growth of SK BR3 cells in serum.
Figures 5a, 5b and 6a show percent viability of SK BR3 cells as a function of increasing TNF-a concentration and anti-HER2 p185 monoclonal antibody concentration. Each Figure shows the results for a different anti-HER2 p185 monoclonal antibody. Figure 6b is a control using an irrelevant monoclonal antibody.
Figure 7 shows percent viability of MDA-MB-175-VII cells as a function of increasing TNF-a concentration and anti-HER2 p185 monoclonal antibody concentration.
Figure 8 shows percent viability of NIH 3T3 cells overexpressing HER:? p185 as a function of increasing TNF-a concentration and anti-HER2 p185 monoclonal antibody concentration.
Detailed Description of the Invention A new application of antibodies to inhibit the growth of tumor cells has been discovered. Surprisingly, it has been found that by inhibiting growth factor receptor function, e.g. the HER2 receptor function, cell growth is inhibited, and the cells are rendered more susceptible to cytot:oxic factors. Thus, for example, breast cancer cells which fire refractory to TNF-a alone can be made susceptible to TNF-a if the cells are first treated with antibodies which inhibit growth factor receptor function. The increase of susceptibility has 'been demonstrated using the HER2 receptor and monoclonal antibodies directed against the HER2 receptor, and tumor necrosis factor-a.
The method of this invention is useful in the therapy of malignant or benign tumors of mammals where the abnormal growth rate of the tumor is dependent upon growth factor receptors.

~~4~ X82 Abnormal growth rate is a rate of growth which is in excess of that required for normal homeostasis and is in excess of that for normal tissues of the same origin. Many of these tumors are dependent upon extracel.lular sources of the growth factor recognized by the receptor, or upon synthesis of the growth factor by the tumor cell itself. This latter phenomenon is termed "autocrine" growth.
The methods o f the subject invention is applicable where the following conditions are met:
(1) the growth factor receptor and/or ligand (growth factor) is expressed, and tumor cell growth depends upon the growth factor receptor biological function;
(2) antibodies specifically binding the growth factor receptor and/or ligand inhibit the growth factor receptor biological function.
While not wishing to be constrained to any particular theory of operation of the invention, it is believed that the antibodies inhibit growth factor receptor biological function in one or more of the following ways:
(a) The antibodies bind to the extracellular domain of the receptor and inhibit the ligand from binding the receptor;
(b) The antibodies bind the ligand (the growth factor) itself and inhibit the ligand from binding the receptor;
(c) The antibodies down regulate the growth factor receptor;
(d) The antibodies sensitize tumor cells to the cytotoxic effects of a cytotoxi~~ factor such as TNF-a;
(e) The antibodies inhibit the tyrosine kinase activity of the receptor.
In cases (f) .and (g), the antibodies inhibit growth factor receptor biological function indirectly by mediating cytotoxicity via a targeting fun~~tion:
(f) The antibodies belong to a sub-class or isotype that upon complexing with the receptor activates serum complement and/or ~~4~ X82 -lo-mediate antibody-dependent cellular cytotoxicity (ADCC), e.g. IgG2a antibodies;
(g) The antibodies which bind the receptor or growth factor are conjugated to a toxin (immunotoxins);
Advantageously antibodies are selected which greatly inhibit the receptor function try binding the steric vicinity of the ligand binding site of the receptor (blocking the receptor), and/or which bind the growth factor in such a way as to prevent (block) the ligand from binding to the receptor. These antibodies are selected using convent:iona7. in vitro assays for selecting antibodies which neutralize receptor function. Antibodies that act as ligand agonists by mimicking the ligand are discarded by conducting suitable assays as will be apparent to those skilled in the art.
For certain tumor cells, the antibodies inhibit an autocrine growth cycle (i.e. Gfiere a cell secretes a growth factor which then binds to a receptor of the same cell). Since some ligands, e.g. TGF-a, are found lodged in cell membranes, the antibodies serving a targeting function are directed against the ligand and/or the receptor.
Certain tumor cells secrete growth factors that are required for normal cellular growth and division. These growth factors, however, can under some conditions stimulate unregulated growth of the tumor cell itself, as well as adjacent non-tumor cells, and can cause a tumor to form.
Epidermal Growth Factor (EGF) has dramatic stimulatory effects on cell growth. In purified receptor preparations, the EGF
receptor is a protein kinase that is activated by the binding of EGF. Substrate proteins for this kinase are phosphorylated on tyrosine residues, The receptors for insulin, platelet-derived growth factor (PDC~F;1 and other growth hormones also are tyrosine-specific kin~ises. It is believed that ligand binding to the receptor triggers phosphorylation of certain proteins by the receptor and in this way stimulates cell growth. About one-third ~ X41 08 2 of the known oncogenes encode proteins that phosphorylate tyrosine residues on other proteins. It is believed that these oncogene products trigger responses analogous to the responses of cells to growth factors and hormones. The erbB oncogene product is a portion of tine EGF receptor that lacks the hormone-binding domain and may give rise to a constitutive growth-stimulating signal.
One embodiment of this invention is a method of inhibiting the growth of tumor cells by administering to a patient a therapeutically effective amount of antibodies that inhibit the HER2 receptor biological function of tumor cells.
Overexpression of growth factor receptors increases the resistance ofd cells to TNF as demonstrated below. Overexpression of the HER1 receptor (EGF receptor), met receptor-like protooncogene produc t, and HER2 receptor all show this increased resistance. It is shown in the Examples below that amplified expression of HER2, which encodes the HER2 receptor (p185), induces resistance of NIH 3f3 cells to the cytotoxic effects of macrophages or TNF-a. Induction of NIH 3T3 cell resistance to TNF-a by overexpression of p185 is accompanied by alterations in the binding of TNF-a to its receptor. Overexpression of p185 is also associated with resistance of certain human breast tumor cell lines to the cytotoxic effects of TNF-a.
In another embodiment of the invention, tumor cells are treated by I;1) administering to a patient antibodies directed against the growth factor and/or its receptor, that inhibit the biological fwnction of the receptor and that sensitize the cells to cytotoxic factors .such as TNF, and (2) administering to the patient cytotoxic factors) or other biological response modifiers which activate immune system cells directly or indirectly to produce cytotoxic factors.

The cytotoxic factor, such as TNF-a, exerts its cytostatic (cell growth suppressive) and cytotoxic (cell destructive) effect.
Examples of useful cytotoxic factors are TNF-a, TNF-)S, IL-l, IFN-y and IL-2, and chemotherapeutic drugs such as SFU, vinblastine, actinomycin 1), etoposide, cisplatin, methotrexate, and doxorubicin.
Cytotoxic factors can be administered alone or in combination. In a still further embodiment of the invention, the patient is treated with antibodies ~ohich inhibit receptor function, and with autologous transfe r therapy, e.g. LAK or TIL cells.
Tumor necrosis factors are polypeptides produced by mitogen-stimulated macrophages or lymphocytes which are cytotoxic for certain malignantly transformed cells. The anti-tumor effect of TNF-a is known to be synergistically potentiated by interferons.
The anti-tumor effect of TNF-a and TNF-/9 in admixture are additive, as are the antiviral effects of interferons alpha and beta.
The tumor necrosis factors include TNF-a and TNF-~. The former is described together with methods for its synthesis in recombinant cell culture, in U.S. Patent 4,650,674, and in European i Patent Appli.c.0168214(Jan.lS/86); the latter is described in European Patent Applic.0164965 (Dec.l8/85). The TNF-a and TNF-described in these patent documents includes cytotoxic amino acid sequence and gly~~osylation variants. TNF-a and TNF-(3 from non-recombinant sources are also useful in the method of this invention.
The preferred TNF is mature human TNF-a from recombinant microbial ce7_1 culture. The TNF ordinarily will have a cytolytic activity on ::uscep tible L-M murine cells of greater than about 1 x 106 units/mg, wherein a unit is defined as set forth in the above-described patent application.
In another embodiment of the subject invention, one or more additional cytokines~ and/or cytotoxic factors are administered with TNF-a, egs. interferons, interleukins, and chemotherapeutic drugs.

~ 3~r1 08 2 The compositions herein include a pharmaceutically acceptable vehicle such as those heretofore used in the therapeutic administration of interferons or TNF, e.g. physiological saline or 5$ dextrose, together with conventional stabilizers and/or excipients such as human serum albumin or mannitol. The compositions are provided lyophilized or in the form of sterile aqueous solutions.
Several variables will be taken into account by the ordinary artisan in de:termi.ning the concentration of TNF in the therapeutic compositions and the dosages to be administered. Therapeutic variables also include the administration route, and the clinical condition of the patient.
The cytotoxic factors) and antibodies inhibiting growth factor receptor func Lion are administered together or separately.
If the latter, advantageously the antibodies are administered first and the TNF thereafter within 24 hours. It is within the scope of this invention to administer the TNF and antibodies in multiple cycles, depending upon the clinical response of the patient. The TNF and antibodies are administered by the same or separate routes, for example: by intravenous, intranasal or intramuscular administration.
The method of the subject invention can be used with tumor cells which overex.press growth factor receptor and/or ligand where antibodies can be produced which inhibit the growth factor receptor function. A cell (e. g. breast tumor cell) overexpresses a growth factor recept~~r if the number of receptors on the cell exceeds the number on the normal healthy cell (e. g. normal breast tissue cell).
Examples of carcinomas where the HER2 receptor is overexpressed (and thus the method of the subject invention is applicable), are human breast, renal, gastric and salivary gland carcinomas.

~34~ X82 A further embodiment of the invention is an assay for identifying receptors and other proteins having increased tyrosine kinase activity, and for identifying oncogenes that transform cells. Amplification of certain oncogenes encoding tyrosine kinases correlates with TNF-a resistance. If cells are selected for resistance to TNF-a, some of these will have increased tyrosine kinase activity. Some of the tyrosine kinases will be receptors.
The genes encoding the tyrosine kinases are then cloned using standard techniques for the cloning of genes. Identification of the receptor or other protein permits the design of reagents which inhibit receF~tor (o:r other protein) function and induce cellular sensitivity to cyt:ot:oxic factors as demonstrated herein with HER2.
Identification of the receptor also permits subsequent identification of the receptor's ligand. The assay comprises exposing cells suspected to be TNF-a sensitive to TNF-a, and isolating those ce:ils which are TNF-a resistant. The TNF-a resistant cells are then screened for increased tyrosine kinase activity, and receptors and other proteins having increased tyrosine kina;se activity are isolated.
Antibodies In accordance with this invention, monoclonal antibodies specifically binding growth factors or growth factor receptors such as the HER2 receptor, were isolated from continuous hybrid cell lines formed by the fusion of antigen-primed immune lymphocytes with myeloma cells. Advantageously, the monoclonal antibodies of the subject invention which bind growth factor receptors, bind the extracellular domain of the receptors. In another embodiment of the invention, polyclonal antibodies specifically binding the growth factor:; or growth factor receptors are used.
The antibodies of the subject invention which are used in tumor therapy advantageously inhibit tumor cell growth greater than 20$, and most advantageously greater than 50$, in vitro. These antibodies are obtained through screening (see, for example, the 1 34 ~ ~8 2 discussion relating to Figure 3). The anti-HER2 receptor monoclonal antiboc9ies of the subject invention which are used in tumor therap_,~ are capable of inhibiting serum activation of the receptor.
Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore., in contrast to conventional antibody (polyclonal) preparations which typically include dij=ferent: antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Monoclonal antibodies are useful to improve the selectivity and specificity of diagnostic and analytical assay methods using antigen-antibody binding. A
second advantage of monoclonal antibodies is that they are synthesized 'by the hybridoma culture, uncontaminated by other immunoglobulins. Monoclonal antibodies may be prepared from supernatants of cultured hybridoma cells or from ascites induced by intra-peritoneal inoculation of hybridoma cells into mice.
The hybridoma technique described originally by Kohler and Milstein, Eur, J. Immunol. 6, 511 (1976) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens.
The route and schedule of immunization of the host animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. Applicants have employed mice as the test model although it is contemplated that any mammalian subject including human subjects or antibody producing cells therefrom can be manipulated according to the processes of this invention to serve as the basis for production of mammalian, including human, hybrid cell lanes.

After i.mmuni.zation, immune lymphoid cells are fused with myeloma cells to generate a hybrid cell line which can be cultivated .and subcultivated indefinitely, to produce large quantities of monoclonal antibodies. For purposes of this invention, the imu~une lymphoid cells selected for fusion are lymphocytes ;ind their normal differentiated progeny, taken either from lymph rode tissue or spleen tissue from immunized animals.
Applicants prefer to employ immune spleen cells, since they offer a more concentrated and convenient source of antibody producing cells with respect to the mouse system. The myeloma cells provide the basis for continuous propagation of the fused hybrid. Myeloma cells are tumor cells derived from plasma cells.
It is F~ossitale to fuse cells of one species with another.
However, it is preferred that the source of immunized antibody producing cells and myeloma be from the same species.
The hybrid cell. lines can be maintained in culture in vitro in cell culture med~i.a. The cell lines of this invention can be selected and/or maintained in a composition comprising the continuous cell line. in the known hypoxanthine-aminopterinthymidine (HAT) mediuu~. In fact, once the hybridoma cell line is established, it can be maintained on a variety of nutritionally adequate media. Mox-eover, the hybrid cell lines can be stored and preserved in any number of conventional ways, including freezing and storage under liquid nitrogen. Frozen cell lines can be revived and cultured indefinitely with resumed synthesis and secretion of monoclonal antibody. The secreted antibody is recovered from tissue culture supernatant by conventional methods such as precipit:at:ion, ion exchange chromatography, affinity chromatography, or the like.
While the invention is demonstrated using mouse monoclonal antibodies, ~~he invention is not so limited; in fact, human antibodies may be used and may prove to be preferable. Such 1~~~ 082 antibodies can be obtained by using human hybridomas (Cote et al., Monoclonal Antibodies and Cancer Theranv, Alan R. Lisa, p. 77 (1985)). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al. Proc.
Natl. Acad. Sci. 81, 6851 (1984); Neuberger et al., Nature 312, 604 (1984); Takeda et ial., Nature 314, 452 (1985)) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity (such as ability to activate human complement and mediate ADCC) can be used; such antibodies are within the scope of this invention.
As another alternative to the cell fusion technique, EBV
immortalized B cells are used to produce the monoclonal antibodies of the subjects invention. Other methods for producing monoclonal antibodies such as recombinant DNA, are also contemplated.
The immunochemical derivatives of the antibodies of this invention that are of prime importance are (1) immunotoxins (conjugates of the antibody and a cytotoxic moiety) and (2) labeled (e. g. radiolabeled, enzyme-labeled, or fluorochrome-labeled) derivatives in which the label provides a means for identifying immune comple:~ces that include the labeled antibody. The antibodies are also used to induce lysis through the natural complement process, and to interact with antibody dependent cytotoxic cells normally present.
Immunotoxins The cytotoxic moiety of the immunotoxin may be a cytotoxic drug or an ens:ymatically active toxin of bacterial or plant origin, or an enzymatically active fragment ("A chain") of such a toxin.
Enzymatically active toxins and fragments thereof used are diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas seruzinosa), ricin A
chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites 1 3 ~' ~ 8 Z

fordii proteins, dianthin proteins, Ph3~tolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, and enomycin. In another embodiment, the antibodies are conjugated to small molecule anticancer drugs.
Conjugates oj~ the monoclonal antibody and such cytotoxic moieties are made using a variety of bifunctional protein coupling agents.
Examples of such reagents are SPDP, IT, bifunctional derivatives of imidoesters such a dimethyl adipimidate HC1, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bis-azido compounds such as bis (p-azidobenzoyl) hexanediamine, bis-diazonium derivatives such as bis-(p-diazoniumbenzoyl)-ethylenediamine, diisocyanates such as tolylene 2,6-diisocyanate, and bis-active fluorine compounds such as 1,5-difluoro-2,4-dinitrobenzene. The lysing portion of a toxin may be joined to the Fab fragment of the antibodies.
Advantageously, monoclonal antibodies specifically binding the external domain of the target growth factor receptor, e.g. HER2 receptor, are conjugated to ricin A chain. Most advantageously the ricin A chain is deglycosylated and produced through recombinant means. An advantageous method of making the ricin immunotoxin is described in 'ilitetta et al., Science 238, 1098 (1987).
When used to kill human cancer cells in vitro for diagnostic purposes, the conjugates will typically be added to the cell culture medium at a concentration of at least about 10 nM. The formulation and mode of administration for in vitro use are not critical. Aqueous formulations that are compatible with the culture or perfusion medium will normally be used. Cytotoxicity may be read by conventional techniques to determine the presence or degree of cancer .
Cytotoxic: radiopharmaceuticals for treating cancer may be made by conjugating radioactive isotopes (e.g. I, Y, Pr) to the ~'~4 ~ ~$ 2 antibodies. The t:erm "cytotoxic moiety" as used herein is intended to include such isotopes.
In another embodiment, liposomes are filled with a cytotoxic drug and the liposomes are coated with antibodies specifically binding a growth factor receptor. Since there are many receptor sites, this method permits delivery of large amounts of drug to the correct cell type.
Antibodv Dependent Cellular ~~totoxicitv_ The present 3.nvention also involves a method based on the use of antibodies which are (a) directed against growth factor receptors su~=h as HER2 p185, and (b) belong to a subclass or isotype that is capable of mediating the lysis of tumor cells to which the antibody molecule binds. More specifically, these antibodies should belong to a subclass or isotype that, upon complexing with growth factor receptors, activates serum complement and/or mediates antibody dependent cellular cytotoxicity (ADCC) by activating effect:or cells such as natural killer cells or macrophages.
The present nvention is also directed to the use of these antibodies, in their native form, for therapy of human tumors. For example, many IgG2a and IgG3 mouse antibodies which bind tumor.
associated cell surface antigens can be used in vivo for tumor therapy. In fact:, since HER2 p185 is present on a variety of tumors, the subject: antibodies and their therapeutic use have general applicability.
Biologic~il activity of antibodies is known to be determined, to a large extenvt, by the Fc region of the antibody molecule (Uananue and Benace rraf, Textbook of Immunoloey, 2nd Edition, Williams & WiT.kins;, p. 218 (1984)). This includes their ability to activate complement and to mediate antibody-dependent cellular cytotoxicity (ADCC) as effected by leukocytes. Antibodies of -20- , different classes and subclasses differ in this respect, and, according to the present invention, antibodies of those classes having the desired biological activity are selected. For example, mouse immuno~;lobul.ins of the IgG3 and IgG2a class are capable of activating serum complement upon binding to the target cells which express the cognate antigen.
In general, antibodies of the IgG2a and IgG3 subclass and occasionally IgGl can mediate ADCC, and antibodies of the IgG3, and IgG2a and IgM subclasses bind and activate serum complement.
Complement acaivat~ion generally requires the binding of at least two IgG molecules in close proximity on the target cell. However, the binding of only one IgM molecule activates serum complement.
The ability of any particular antibody to mediate lysis of the tumor cell target: by complement activation and/or ADCC can be assayed. The tumor cells of interest are grown and labeled in vivo; the antibody is added to the tumor cell culture in combination with e.it:her serum complement or immune cells which may be activated by the antigen antibody complexes. Cytolysis of the target tumor cells is detected by the release of label from the lysed cells. In fact, antibodies can be screened using the patient's own serum as a source of complement and/or immune cells.
The antibody that is capable of activating complement or mediating ADCC in the in_ vitro test can then be used therapeutically in that particular patient.
Antibodies of virtually any origin can be used according to this embodiment of the present invention provided they bind growth factor receptors such as HER2 p185 and can activate complement or mediate ADCC. Monoclonal antibodies offer the advantage of a continuous, ample supply. In fact, by immunizing mice with, for example, HER2 p18_'i, establishing hybridomas making antibodies to p185 and selecting hybridomas making antibodies which can lyse tumor cells in the presence of human complement, it is possible to X34? 082 rapidly establish a panel of antibodies capable of reacting with and lysing a large>. variety of human tumors.
Therapeutic ilses of the Antibodies When used in vivo for therapy, the antibodies of the subject invention are administered to the patient in therapeutically effective amounts (i.e. amounts that eliminate or reduce the patient's tLUnor burden). They will normally be administered parenterally, when possible, at the target cell site, or intravenously. The dose and dosage regimen will depend upon the nature of the cancer (primary or metastatic), its population, the site to which the antibodies are to be directed, the characteristics of the particular immunotoxin (when used), e.g., its therapeutic index, the patient, and the patient's history. The amount of an~ibody administered will typically be in the range of about 0.1 to about: 1.0 mg/kg of patient weight.
For paxenteral administration the antibodies will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vEShicle. Such vehicles are inherently nontoxic, and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5$ human serum albumin.
Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. Liposomes a~ay be used as carriers. The vehicle may contain minor amounts of-.' additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The antibodies will typically be formulated in such vehicles at concentrations of about 1 mg/ml to 10 mg/ml.
The selection of an antibody subclass for therapy will depend upon the nature o!: the tumor antigen. For example, an IgM may be preferred in situat:Lons where the antigen is highly specific for the tumor tar;~et and rarely occurs on normal cells. However, where the tumor-associated antigen is also expressed in normal tissues, _22_ albeit at much lower levels, the IgG subclass may be preferred for the following reason: since the binding of at least two IgG
molecules in close proximity is required to activate complement, less complement mediated damage may occur in the normal tissues which express: smaller amounts of the antigen and, therefore, bind fewer IgG antibody molecules. Furthermore, IgG molecules by being smaller may he more able than IgM molecules to localize to tumor tissue.
There is. evidence that complement activation ~n vivo leads to a variety of biological effects, including the induction of an inflammatory response and the activation of macrophages (Uananue and Benecerraf, Textbook of Immunolo v, 2nd Edition, Williams &
Wilkins, p. 218 (1984)). Tumor cells are more sensitive to a cytolytic effect .of activated macrophages than are normal cells, Fidler and Poste, Syringer Semin. Immunopathol _5, 161 (1982). The increased vas;odilation accompanying inflammation may increase the ability of various anti-cancer agents, such as chemotherapeutic drugs, radio:Labelled antibodies, etc., to localize in tumors.
Therefore, antigen-antibody combinations of the type specified by this invention can be used therapeutically in many ways and may circumvent many of the problems normally caused by the heterogeneity of 'tumor cell populations. Additionally, purified antigens (Hak:omori., Ann. Rev. Immunol 2_, 103 (1984)) or anti-idiotypic antibodies (Nepom et al., Proc. Natl. Acad Sci 81, 2864 (1985); Koprowski et .~1., Proc. Natl. Acad Sci 81, 216 (1984)) relating to such antigens could be used to induce an active immune response in human cancer patients. Such a response includes the formation of antibodies capable of activating human complement and mediating ADGG and by such mechanisms cause tumor destruction.
Immuno a s s air s Described herein are serological methods for determining the presence of HER2 p185. Essentially, the processes of this invention comprise incubating or otherwise exposing the sample to ~34~ X82 be tested to monoclonal antibodies and detecting the presence of a reaction product. Those skilled in the art will recognize that there are many variations of these basic procedures. These include, for example, RIA, ELISA, precipitation, agglutination, complement fixation and immuno-fluorescence. In the currently preferred procedures, the monoclonal antibodies are appropriately labeled.
The labels that are used in making labeled versions of the antibodies include moieties that may be detected directly, such as radiolabels and fluorochromes, as well as moieties, such as enzymes, that must: be reacted or derivatized to be detected. The radiolabel c~3n be detected by any of the currently available counting procedures. The preferred isotope labels are 99Tc, 14C, 131I~ 125I~ 3H~ 3:?p and 355. The enzyme label can be detected by any of the currently utilized calorimetric, spectrophotometric, fluorospectro-photometric or gasometric techniques. The enzyme is combined with the antibody with bridging molecules such as carbodiimides, periodate, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be uti.li.zed. Examples are peroxidase, alkaline phosphatase, ~-glucuronidase, ~-D-glucosidase, ~-D-galactosidase, unease, glucose oxidise plus peroxidase, galactose oxidise plus peroxidase and acid phosphatase. Fluorescent materials which may be used include, for example, fluorescein and its derivatives, rhodamine and its derivatives, suramine, dansyl, umbelliferone, luciferia, 2,3-dihydrophthalazinediones, horseradish peroxidase, alkaline ptiosphatas~e, lysozyme, and glucose-6-phosphate dehydrogenase.. The antibodies may be tagged with such labels by known methods. For instance, coupling agents such as aldehydes, carbodiimides, dimaleimide, imidates, succinimides, bid-diazotized benzadine and the like may be used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels.
Various labeling techniques are described in Morrison, Methods in ~ 34 ~ 0 EnzvmoloEV 3_2h, 1.03 (1974), Syvanen et al., J. Biol. Chem. 284, 3762 (1973) and Bolton and Hunter, Biochem J. 133, 529 (1973).
The antibodies and labeled antibodies may be used in a variety of immunoima~;ing or immunoassay procedures to detect the presence of cancer in a pat:Cent or monitor the status of such cancer in a patient alre~3dy diagnosed to have it. When used to monitor the status of a cancer, a quantitative immunoassay procedure must be used. If such monitoring assays are carried out periodically and the results compared, a determination may be made regarding whether the patient',s tumor burden has increased or decreased. Common assay techniques that may be used include direct and indirect assays. If t:he sample includes cancer cells, the labeled antibody will bind to those cells. After washing the tissue or cells to remove unbound labeled antibody, the tissue sample is read for the presence of labe7Led immune complexes. In indirect assays the tissue or cell sample is incubated with unlabeled monoclonal antibody. The sample is then treated with a labeled antibody against the monoc:Conal antibody (e. g., a labeled antimurine antibody), washed, a.nd read for the presence of ternary complexes.
For diiignostic use the antibodies will typically be distributed in kit: form. These kits will typically comprise: the antibody in labeled or unlabeled form in suitable containers, reagents for the incubations for an indirect assay, and substrates or derivatizing agents depending on the nature of the label. HER2 p185 controls and instructions may also be included.
The following examples are offered to more fully illustrate the invention, but: .are not to be construed as limiting the scope thereof.

~34~ 082 EXPERIMENTAh Amplified E~~pression of n185HER2 and Tyrosine Kinase Activity A series of NIH 3T3 cell lines expressing various levels of p185 were constructed as disclosed in Hudziak et al. , Proc. Natl.
Acad. Sci. USA_ ~4, 7159 (1987). The parental cell line had a nontransfornaed, 'TNF-a-sensitive phenotype. The control cell line (NIH 3T3 neo/dhfr) was prepared by transfection with pCVN, an expression plasmid encoding neomycin resistance as a selectable marker, and dihydrofolate reductase (which encodes methotrexate resistance and which permits amplification of associated DNA
sequences). pCVN-HER2 (Which encodes, in addition, the entire 1255 amino acid p18_'i receptor-like tyrosine kinase under the transcriptional control of the RSV-LTR) was introduced into NIH 3T3 cells in a parallel transfection. Transfectants were selected by resistance '.to the aminoglycoside antibiotic 6418. The pCVN-HER2 primary transfect:ants (HER2-3) do not have a transformed morphology and fail to grout in soft agar. Stepwise amplification of HER2 expression t>y selection in 200nM (HER2-3200), 400 nM (HER2-3400 ) ,j and 800 mM (HER2-3800) methotrexate, however, results in transformation a:~ judged by morphological criteria, the ability to grow in soft agar', and the ability to form tumors in nude mice.
The amvplification of expression of p185 was documented by immunoprecipitation from cells that were metabolically labeled with 355-methionine. The tyrosine kinase activity associated with p185 in these cell lines was measured by autophosphorylation in vitro.
For an auto:radiograph of 35S-methionine labeled p185, 200 pCi of 355-methionine (Amersham; 1132 Ci/mmol) was added to 1.5 ml of methionine-free labeling medium, containing 2$ dialyzed fetal bovine serum. 1.~0 x 106 cells of each type were counted by Coulter counter, plated in 60 mm culture dishes (Falcon)*, and allowed to adhere for 12 h. Following an 8 h labeling period the cells were lysed and the HER2-encoded p185 was analyzed. For an autoradiograph of self-phosphorylated HER2-receptor tyrosine kinase, the p185 was immunoprecipitated and the pellet was *trade-mark ~ 34 ~ ~8 2 resuspended in :50 ~cl of tyrosine kinase reaction buffer.
samples were incubated at 4°C for 20 min. The self-phosphorylated p185 from the various cell lines was then visualized by autoradiography following gel electrophoresis. The molecular weight markers used were myosin (200kD) and ~-galactosidase (116kD). 'Che re::ults showed that expression of p185 and its associated tyrosine kinase increased in parallel during amplificat-i_cn. Quantitative densitometry of the in vitro autophosphorylatiori reactions showed that the tyrosine kinase activity in<:reased at least 5 to 6-fold between HER2-3 and HER2-3200 and between HER2-3200 and HER2-3400~ while only a small difference was observed' between HER2-3400 and HER2-3800 (see the Tyrosine Kinase column of Table 1 below).
Relative amounts of tyrosine kinase present in each of the cell types of Table 1 were determined by taking ratios of the areas .under the curves obtained by scanning autoradiograms (using an LKB2202*laser densitometer). The autoradiograms had been exposed for various times to allow for linearity in the determinations, and then normalized by comparison to the HER2 primary transfectant (HER2-3).
Resistance to TNF-a The cell lines described above were then tested for sensitivity Lo TNl~-cx and macrophage-induced cytotoxicity.
In Figure la, TNF-a resistance of the control cells and the HER2-transfec:ted NIH 3T3 cells is shown. Cells were seeded into 96-well microtiter plates at a density of 5,000 cells/well in DMEM
supplemented with 10$ calf serum, 2mM L-glutamine, 100 U/ml penicillin and 100 ~g/ml streptomycin. The cells were allowed to adhere for 4 hrs before the addition of a range of concentrations of TNF-a. SF~ecifi.c activity of the TNF-a (recombinant human TNF-a) was 5 x 107 L/mg a.s determined in an L-M cell cytotoxicity assay in the presence of actinomycin D. After incubation at 37°C for 72 hr, * trade--mark the monolayers were washed with PBS and stained with crystal violet dye for determination of relative cell viability. These measurements were repeated six times. Results from a representative experiment are shown in Figure la.
In Figure 1'b, macrophage-mediated cytotoxicity assays are shown. TNF~-a re~s~:stant cells (neo/dhfr HTR) . were derived by subculturing a clone of NIH 3T3 neo/dhfr in media containing 10,000 U/ml TNF-a. For macrophage cytotoxicity assays, NIH 3T3 neo/dhfr, HER2-3g00 anal ne>.o/dhfr HTR cells were seeded into 96-well microtiter plates as in la above. Human macrophages were obtained as adherent cells from peripheral blood of healthy donors.
Adherent cell's were scraped and resuspended in media, activated for 4 hr. with 10 ~g/ml E. coli-derived lipopolysaccharide (LPS; Sigma) and 100 U/m:of recombinant human interferon-gamma (rHuIFN-~, Genentech, In~~.). The cell suspension was then centrifuged for 10 minutes at 1200 rpm and the resulting pellet was washed with media to remove the LPS and rHuIFN-y. The macrophages were resuspended in media, counted, and then added to the target cells to obtain the desired effector too target ratios. After a 72 hr incubation at 37°C, the monolayers were washed with media and SlCr was added to each well for determination of viability by SlCr uptake.

~2 _28_ Table 1 Correlation between HER2-associated tyrosine kinase levels and resistance to TNF-a Percent Tyrosine Cell Type-- Viability Kinase 1. NIH 3T3 neo/dhfr 3.6 +0.6 2. NIH 3T3 neo/dhfr4008.3 +1.0 3. HER2-3 2.0 +0.4 1.0 4. HER2-3200 27.5 +2.7 6.73 5. HER2-3400 48.4 +1.4 32.48 6. HER2-3800 58.7 +1.3 39.61 7. BT-20 1.6 +0.3 <0.1 8. MCF7 2.5 +0.3 0.26 9. MDA-MB-361 26.8 +6.6 10.65 10. MDA-MB-175-VII 31.2 +4.4 0.9 11. SK-BR-3 56.4 +5.5 31.0 12. MDA-MB-231 64.2 +9.3 <0.1 * not measured Percent viability is given at 1.0 x 104 cytotoxicity units per ml of TNF-a. Th.e breast tumor cell lines were obtained from the ATCC
and maintained in DMEM supplemented with 10$ fetal bovine serum, 2 mM glutamine, 100 'U/ml penicillin and 100 ~g/ml streptomycin.
As shown in Fig. la and Table 1, stepwise amplification of HER2 receptor expression resulted in a parallel induction of resistance to TNF-a. The primary transfectants (HER2-3), which do not have a l~ransformed phenotype, demonstrated little increased resistance. However, the transformed lines HER2-3200, HER2-3400 and HER2-3800 do show a stepwise loss in sensitivity to TNF-a-mediated cytotoxicit;y as compared to NIH 3T3 neo/dhfr (Fig. la and Table 1), althoug~,h the MDA-MB-175-VII cells had elevated p185 expression compared to the TNF-a sensitive BT20 and MCF7 cell lines. In correlation with the levels of p185 expression (Table 1), the difference in sensitivity of HER2-3200 and HER2-3400 (27.5$

134' ~8 vs. 48.4$ viability at 1 x 104 U/ml TNF-a) is greater than the difference between HER2-3400 and HER2-3800 (48.4$ vs. 58.7$
viability, se:e Fig. la and Table 1). A similar result was obtained when NIH 3T3 neo/dhfr and HER2-3800 were compared for sensitivity to activated macrophages (Fig. lb). These data suggest that amplification of the expression of HER2 induces resistance to TNF-a, and also show that this correlates with resistance to an important component: of the early host defense mechanism, the activated macrophage. Amplification of the control plasmid (pCVN) in the cell line NIH 3T3 neo/dhfr400 did not induce increased resistance to TNF-a (Table 1). This demonstrates that neither gene transfection or gene amplification, per se, has any effect on the sensitivity of cells; to TNF-a.
The observation that NIH 3T3 cell lines expressing high levels of p185 were resistant to cytotoxicity induced by TNF-a or macrophages suggested that this may be one mechanism leading to tumor development. To test this possibility six breast tumor cell lines were screened for amplification of HER2 and sensitivity to TNF-a-mediated cytotoxicity. The results (Table 1) demonstrated that sensitivity to growth inhibition by TNF-a is inversely correlated with tile expression of HER2-associated tyrosine kinase measured in ~ritro autophosphorylation assay for BT-20, MCF7, MDA-MB-361 and SY:-BR-~I. Two of the TNF-a-resistant breast tumor cell lines (MDA-MB-175-VII and MDA-MB-231), however, had no demonstrable amplified expression of HER2 as compared to the HER2-3 control (Table 1), although the MDA-MB-175-VII cells had elevated p185 expression comparE?d to the TNF-a sensitive BT20 and MCF7 cell lines. These results are consistent with previous reports of the frequency of 1HER2 amplification in primary breast tumors and tumor-derived cell lines, and suggest the existence of other cellular mechanisms which may lead to TNF-a resistance.

134' 08 Experiments a:Lso showed that overexpression of the EGF
receptor, and cellular transformation by the src oncogene, correlates with resistance to TNF-a.
TNF-a Receptor Bindine In order to investigate whether the TNF-a receptor was altered in HER2-3800, as opposed to NIH 3T3 neo/dhfr, the binding of 125I-labeled TNF-~x was compared between these cell lines. Figure 2 shows a TNF-ct receptor binding analysis. Displacement curves show binding of 1251-TNF-a to NIH 3T3 neo/dhfr and HER2-3800.
Competition binding assays were performed. Briefly, a suspension of 2.0 x 106 cells were incubated in a final volume of 0.5 ml of RPMI-1640 medium containing 10~ fetal bovine serum. Binding of 125I_TNF-a (0.2 x 106 cpm) to the cells was determined in the presence or absence of varying concentrations of unlabeled TNF-a at 4°C under s~atura~tion equilibrium conditions. Each data point represents the mean of triplicate determinations. After incubation overnight, cells were washed twice with incubation buffer and cell bound radioactivity was determined. Non-specific binding was <10~
of total binding.
The results showed a 2-3 fold increase in total specific binding for HER2-3800 as compared to NIH 3T3 neo/dhfr (Fig. 2). In addition, the displacement curve for binding on HER2-3800 is also shifted towa~_d lower affinity binding as compared to NIH 3T3 neo/dhfr (Fig. 2).
Production of Anti-HER2 Monoclonal Antibodies Five female Balb/c mice were immunized with HER2 amplified NIH
3T3 transformed cells over a period of 22 weeks. The first four injections each had approximately 107 cells/mouse. They were administered :Lntrape:ritoneally in half a milliliter of PBS on weeks 0, 2, 5, 7. Injections five and six were with a wheat germ agglutinin partially purified membrane preparation which had a whole protein concE>ntration of about 700 ~ag/ml. A 100 ~1/injection ~3'~~0 was administered t:o each mouse intraperitoneally on weeks 9 and 13.
The last injection was also with the purified material but was administered threes days prior to the date of fusion intravenously.
Bleeds from the mice were tested at various times in a radioimmunoprecipitation using whole cell lysates. The three mice with the highest antibody titers were sacrificed and spleens were fused with the mouse myeloma cell line X63-Ag8.653 i,,~ing the general procedure ofd Mishell & Shiigi, Selected Methods in Cellular Immunoloey. Id. H. Freeman & Co., San Francisco, p. 357-363 (1980) with the following exceptions. Cells were plated at a density of approximately 2 x 105 cells/well into ten 96 well microtiter plates. Hyb~~ids were selected using hypoxanthine-azoserine rather than hypoxanthine-aminoptern-thymidine (HAT).
Hybridoa;a supernatants were tested for presence of antibodies specific for HER2 receptor by ELISA and radioimmunoprecipitation.
For the ELISA., 3.5 ~sg/ml of the HER2 receptor (purified on the wheat germ agglutinin column) in PBS was adsorbed to immulon ITk microtiter plates overnight at 4°C or for 2 hours at room temperature. Plates were then washed with phosphate buffered saline with .OS$ Tween* 20 (PBS-TW20) to remove unbound antigen.
Remaining binding sites were then blocked with 200 ~1 per well of 1$ bovine serum albumin (BSA) in PBS-TW20 and incubated 1 hour at room tempera~~ure. Plates were washed as above and 100 dal of hybridoma supernatant was added to each well and incubated for 1 hour at room temperature. Plates were washed again and 100 ~1 per well of an appropriate dilution of goat anti-mouse immunoglobulin coupled to H;~orseradish peroxidase was added. The plates were incubated again for 1 hour at room temperature and then washed as above. O-phe~nylene diamine was added as substrate, incubated for 15-20 minutes at room temperature and then the reaction was stopped with 2.5 M H2;S04. The absorbance of each well was then read at 492 nm.
*trade-mark 13~1D
_32_ 8 2 For th~s radi.oimmunoprecipitation, first the wheat germ purified HER:2 receptor preparation was autophosphorylated in the following manner: a kinase solution with the following final concentratiora was made: .18 mCi/ml ~P32-ATP (Amersham), .4mM
MgCl2, .2mM JKnCl2, lO~cM ATP, 35 ~cg/ml total protein concentration of partially purified HER2 all diluted in 20mM Hepes, 0.1$ triton 10$ glycerol buffer (HTG). This reaction was incubated for 30 minutes at room temperature. 50 pl hybridoma supernatant was then added to 50 ~,~1 of the kinase reaction and incubated 1 hour at room temperature. 50 dal of goat anti-mouse IgG precoated protein-A
sepharose CL4B, at a. sepharose concentration of 80 mg/ml, was added to each sample and incubated 1 hour at room temperature. The resulting ima:unoco~mplexes'were then washed by centrifugation twice with HTG buffer and finally with .2$ deoxycholate .2$ Tween 20*in PBS, in a microfuge and aspirated between washes. Reducing sample buffer was added to each sample and samples were heated at 95°C for-2-5 minutes, inso:Luble material was removed by centrifugation and the reduced immunocomplex was loaded onto a 7.5$ polyacrylamide gel containing SDS. T'he gel was run at 30 amp constant current and an autoradiograph was obtained from the finished gel.
Approximately 5$ of the total well supernatants reacted with the HER2 receptor in the ELISA and/or radioimmunoprecipitation.
From this initia:L 5$ (about 100), some hybrids produced low affinity antibodies and others suffered from instability and stopped secreting antibodies leaving a total of 10 high affinity stable HER2 ;speci:fic antibody producing cell lines. These were expanded and cloned by limiting dilution (Oi, V.T. and Herzenberg, L.A., "Immunoglobulin Producing Hybrid Cell Lines" in Selected Methods in Cellular Immunolor~y, p. 351-372 Mishell, B.B. and Shiigi, S.M. (eds.), W.H. Freeman and Co. (1980)). Large quantities oi_ specific monoclonal antibodies were produced by injection of cloned hybridoma cells in pristaned primed mice to *trade-mark n ~34~ ~8Z

produce ascitic tumors. Ascites were then collected and purified over a protein-A s;epharose column.
Screeninr~ of Antibodies The 10 high affinity monoclonal antibodies were then screened in a number of assays for anti-transformation or anti-tumor cell activity. rfonocl_onal antibodies were selected on the basis of growth inhibiting activity against the human tumor line SK BR3 which is derived from a breast tumor and contains an amplified HER2 gene and overexpreases the HER2 p185 tyrosine kinase. The initial screen used condi.ti.oned medium (medium in which the cells were grown for several. days containing any secreted products of the cells including antibodies produced by the cells) from the hybridoma cell lines.
SK BR3 cells were plated at 20,000 cells/35 mm dish. Either conditioned :medium from the hybridoma parent line (producing everything but anti-HER2 monoclonals) as a control, or the anti-HER2 monoclonals were added. After 6 days, the total number of SK
BR3 cells were counted using an electronic Coulter cell counter.
Cells were grown in. a 1:1 mixture of F-12 and DMEM supplemented With 10$ fetal bovine serum, glutamine, and penicillinstreptomycin.
The volume par pl.at:e was 2 mls/35mm dish. 0.2 mls of myeloma conditioned medium was added per 35mm dish. Each control or anti-HER2 MAb was ;assayad in duplicate and the two counts averaged.
The result oi: the survey is shown in Figure 3. Monoclonal antibody 4D5 markedly inhibited the growth of the breast tumor line SK BR3. Other anti-HER2 antibodies inhibited growth to a significant but lesser extent (egs., MAbs 3E8 and 3H4). Still other anti-HER2 antibodies (not shown) did not inhibit growth.
A repeal: experiment using purified antibody rather than hybridoma conditioned medium confirmed the results of Figure 3.
Figure 4 is a dose response curve comparing the effect of an irrelevant monoclonal antibody (anti-HBV) and monoclonal antibody 4D5 (anti-HER.2) on the growth of the SK BR3 cell line in 10~ fetal bovine serum.
Down Regulation of the HER2 Receptor The SK BR3 cells were pulse labeled with 100uci 35S-methionine for 12 hours in methionine-free medium. Then either an irrelevant (anti-Hepatitis B surface antigen) or anti-HER2 MAb (4D5) was added to the cells at 5 ~cg/ml. After 11 hours, the cells were lysed and HER2 p185 immunoprecipitates and the proteins were analyzed by a 7.5~ acrylamide gel followed by autoradiography. The SDS-PAGE gel of the 35S-methionine labeled HER2 p185 from SK BR3 cells demonstrated that the HER2 levels are downregulated by MAb 4D5.
Treatment of :Breast Tumor Cells with Monoclonal Antibodies and TNF-a SK-BR-3 'breast tumor cells were seeded at a density of 4 x 104 cells per well in 96-well microtiter plates and allowed to adhere for 2 hours. The cells were then treated with different concentration's of anti-HER2 monoclonal antibody (MAb) 4D5 or irrelevant isotype matched (anti-rHuIFN-7 MAb) at 0.05, 0.5 or 5.0 ~g/ml for 4 hours prior to the addition of 100, 1,000 or 10,000 U/ml rHuTNF-a. After a 72 hour incubation, the cell monolayers were stained with crystal violet dye for determination of relative percent viability (RPV) compared to control (untreated) cells.
Each treatment group consisted of 6 replicates. The results are shown in Figures .'i and 6. These Figures show that incubation of cells overexpressiwg HER2 receptor with antibodies directed to the extracellular domain of the receptor induce sensitivity to the cytotoxic effects of TNF-a. Equivalent treatment of breast tumor cells MDA-MB-175 VII gave similar results (see Figure 7).
Treatment of human fetal lung fibroblasts (WI-38) with MAb resulted in no growth inhibition or induction of sensitivity to TNF-a as expected.

'~~ ~ o Treatment of NIH 3T3 Cells Overexpressing HER2 p185 with Monoclonal Antibodies ar.d TNf-a NIH 3T3 HF:R:?-3400 cells were treated with different concentrations of anti-HER2 MAbs as in the above described treatment of SK-BR3 cells. The results for MAb 4D5 are shown in Figure 8. The results indicate that cells other than of breast tumor cell lines which overexpress the HER2 receptor are growth inhibited by antibodies to the HER2 receptor, and sensitivity to TNF-a is induced in the presence of these antibodies.
In Vivo Treatment of NIH 3T3 Cells Overexpressing HER2 with Anti-HER2 I~,G2A Monoclonal Antibodies NIH 3T3 cells transfected with either a HER2 expression plasmid (NIH 3T34.00) or the neo-DHFR vector were injected into nu/nu (athymic) mice subcutaneously at a dose of 106 cells in 0.1 ml of phosphate-buffered saline. On days 0, 1, 5 and every 4 days thereafter, 100 ~g (0.1 ml in PBS) of either an irrelevant or anti HER2 monoclonal antibody of the IgG2A subclass was injected intraperitoneally. Tumor occurrence and size were monitored for the 1 month period of treatment.
Table 2 Tumor Size of Survivors:
Length x Width # Tumors/ Average in mm2 Group # Cell Line Treatment # Animals at 31 Days 1 HER2 (3T3400) Irrelevant MAb (anti-Hepatitis B Virus) 6/6 401 2 HER2 (:3T3400) 2H11 anti-HER2 2/6 139 3 HER2 (:3T3400) 3E8 anti-HER2 0/6 0 4 neo/DHIG'R None 0/6 0 $2 Table 2 show:> that the 2H11 MAb has some anti-tumor activity (MAb 2H11 has very slight growth inhibiting properties when screened against tumor lines :>K BR3) and the 3E8 MAb gives 100% tumor growth inhibition during the course of the experiment.
While the invention has been described in what is considered to be its preferred embodiments, it is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modii_icat:ions and equivalents included within the spirit and scope of the appended claims, which scope is to be accorded the broadest inte~rpretat:ion so as to encompass all such modifications and equivalents.

Claims (149)

1. An monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor, said antibody having a growth inhibitory characteristic of the monoclonal antibody 4D5 (ATCC CRL 10463) of inhibiting growth in vitro of SK-BR-3 breast tumor cells overexpressing said HER2 receptor.
2. The antibody of claim 1 which inhibits growth of said SK-BR-3 breast tumor cells in vitro by greater than 20% after a six day assay.
3. The antibody of claim 2 which inhibits growth of said SK-BR-3 breast. tumor cells in vitro by greater than 50% after said six day assay.
4. The antibody of claim 1 which is capable of inhibiting HER2 receptor function.
5. The antibody of claim 2 which is capable of inhibiting HER2 receptor function.
6. The antibody of claim 3 which is capable of inhibiting HER2 receptor function.
7. The antibody of claim 4 which is capable of inhibiting serum activation of HER2 receptor function.
8. The antibody of claim 5 which is capable of inhibiting serum activation of HER2 receptor function.
9. The antibody of claim 6 which is capable of inhibiting serum activation of HER2 receptor function.
10. The antibody of any one of claims 1 to 9 which is a monoclonal antibody.
11. The antibody of claim 10 which is a murine monoclonal antibody.
12. The antibody of any one of claims 1 to 9 or 11 which is a chimeric antibody.
13. The antibody of claim 10 which is a chimeric antibody.
14. The antibody of any one of claims 1 to 9, 11 or 13 which specifically blocks the ligand binding site of said HER2 receptor.
15. The antibody of claim 10 which specifically blocks the ligand binding site of said HER2 receptor.
16. The antibody of claim 12 which specifically blocks the ligand binding site of said HER2 receptor.
17. The antibody of any one of claims 1 to 9, 11, 13, 15 or 16 which downregulates said HER2 receptor.
18. The antibody of claim 10 which downregulates said HER2 receptor.
19. The antibody of claim 12 which downregulates said HER2 receptor.
20. The antibody of claim 14 which downregulates said HER2 receptor.
21. The antibody of any one of claims 1 to 9, 11, 13, 15, 16 or 18 to 20 which activates complement.
22. The antibody of claim 10 which activates complement.
23. The antibody of claim 12 which activates complement.
24. The antibody of claim 14 which activates complement.
25. The antibody of claim 17 which activates complement.
26. The antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20 or 22 to 25 which mediates antibody dependent cellular cytotoxicity.
27. The antibody of claim 10 which mediates antibody dependent cellular cytotoxicity.
28. The antibody of claim 12 which mediates antibody dependent cellular cytotoxicity.
29. The antibody of claim 14 which mediates antibody dependent cellular cytotoxicity.
30. The antibody of claim 17 which mediates antibody dependent cellular cytotoxicity.
31. The antibody of claim 21 which mediates antibody dependent cellular cytotoxicity.
32. The antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20, 22 to 25 or 27 to 31 which sensitizes tumor cells to a cytotoxic factor.
33. The antibody of claim 10 which sensitizes tumor cells to a cytotoxic factor.
34. The antibody of claim 12 which sensitizes tumor cells to a cytotoxic factor.
35. The antibody of claim 14 which sensitizes tumor cells to a cytotoxic factor.
36. The antibody of claim 17 which sensitizes tumor cells to a cytotoxic factor.
37. The antibody of claim 21 which sensitizes tumor cells to a cytotoxic factor.
38. The antibody of claim 26 which sensitizes tumor cells to a cytotoxic factor.
39. The antibody of claim 32 wherein said cytotoxic factor is TNF-.alpha..
40. The antibody of any one of claims 33 to 38 wherein said cytotoxic factor is TNF-.alpha..
41. The antibody of claim 1 which is 4D5.
42. The antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20, 22 to 25, 27 to 31, 33 to 39 or 41 which is labeled.
43. The antibody of claim 10 which is labeled.
44. The antibody of claim 12 which is labeled.
45. The antibody of claim 14 which is labeled.
46. The antibody of claim 17 which is labeled.
47. The antibody of claim 21 which is labeled.
48. The antibody of claim 26 which is labeled.
49. The antibody of claim 32 which is labeled.
50. The antibody of claim 40 which is labeled.
51. The antibody of claim 42 wherein the label is radiolabel, enzyme label or fluorochrome label.
52. The antibody of any one of claims 43 to 50 wherein the label is radiolabel, enzyme label or fluorochrome label.
53. A composition comprising said antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20, 22 to 25, 27 to 31, 33 to 39, 41 or 43 to 51 and a cytotoxic factor.
\
54. A composition comprising said antibody of claim 10 and a cytotoxic factor.
55. A composition comprising said antibody of claim 12 and a cytotoxic factor.
56. A composition comprising said antibody of claim 14 and a cytotoxic factor.
57. A composition comprising said antibody of claim 17 and a cytotoxic factor.
58. A composition comprising said antibody of claim 21 and a cytoroxic factor.
59. A composition comprising said antibody of claim 26 and a cytoxoxic factor.
60. A composition comprising said antibody of claim 32 and a cytotoxic factor.
61. A composition comprising said antibody of claim 40 and a cytotoxic factor.
62. A composition comprising said antibody of claim 42 and a cytotoxic factor.
63. A composition comprising said antibody of claim 52 and a cytotoxic factor.
64. The composition of claim 53 wherein said cytotoxic factor comprises TNF-.alpha., TNF-.beta., IL-1, IFN-.gamma., IL-2, 5Fu, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate or doxorubicin.
65. The composition of any one of claims 54 to 63 wherein said cytotoxic factor comprises TNF-.alpha., TNF-.beta., IL-1, IFN-.gamma., IL-2, 5Fu, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate or doxorubicin.
66. The composition of claim 64 wherein said cytotoxic factor is cisplatin.
67. The composition of claim 65 wherein said cytotoxic factor is cisplatin.
68. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20, 22 to 25, 27 to 31, 33 to 39 or 41.
69. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 10.
70. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 12.
71. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 14.
72. An immunatoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 17.
73. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 21.
74. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 26.
75. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 32.
76. An immunotoxin which is a conjugate of a cytotoxic moiety and said antibody of claim 40.
77. The immunotoxin of claim 68 wherein said cytotoxic moiety comprises a cytotoxic drug, an enzymatically active toxin of bacterial or plant origin or an enzymatically active fragment thereof.
78. The immunotoxin of any one of claims 69 to 76 wherein said cytotoxic moiety comprises a cytotoxic drug, an enzymatically active toxin of bacterial or plant origin or an enzymatically active fragment thereof.
79. The immunotoxin of claim 68 wherein said cytotoxic moiety comprises a radioactive isotope.
80. The immunotoxin of any one of claims 69 to 76 wherein said cytotoxic moiety comprises a radioactive isotope.
81. The immunotoxin of claim 79 wherein said radioactive isotope comprises I, Y or Pr.
82. The immunotoxin of claim 80 wherein said radioactive isotope comprises I, Y or Pr.
83. A liposome comprising said antibody of claim 1.
84. A hybridoma producing said antibody of claim 1.
85. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20, 22 to 25, 27 to 31, 33 to 39, 41 or 43 to 51 and determining the extent of binding of said antibody to said sample.
86. An essay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 10 and determining the extent of binding of said antibody to said sample.
87. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 12 and determining the extent of binding of said antibody to said sample.
88. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 14 and determining the extent of binding of said antibody to said sample.
89. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 17 and determining the extent of binding of said antibody to said sample.
90. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 21 and determining the extent of binding of said antibody to said sample.
91. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 24 and determining the extent of binding of said antibody to said sample.
92. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 26 and determining the extent of binding of said antibody to said sample.
93. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 32 and determining the extent of binding of said antibody to said sample.
94. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 40 and determining the extent of binding of said antibody to said sample.
95. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 42 and determining the extent of binding of said antibody to said sample.
96. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to said antibody of claim 52 and determining the extent of binding of said antibody to said sample.
97. An assay for detecting a tumor characterized by amplified expression of the HER2 receptor comprising the steps of exposing a sample to a monoclonal antibody which binds to the epitope of the HER2 receptor to which 4D5 (ATCC CRL 10463) binds, and determining the extent of binding of said antibody to said sample.
98. The assay of claim 85 which is an ELISA assay.
99. The assay of any one of claims 86 to 97 which is an ELISA assay.
100. The assay of claim 85 wherein said antibody is tagged with a radioactive isotope and administered to a mammal, and the exaent of binding of said antibody to tissues in the mammal is observed by external scanning for radioactivity.
101. The assay of any one of claims 86 to 97 wherein said antibody is tagged with a radioactive isotope and administered t:o a mammal, and the extent of binding of said antibody to tissues in the mammal is observed by external scanning for radioactivity.
102. The assay of claim 100 wherein said radioactive isotope comprises 99Tc, 14C, 131I, 125I, 3H, 32p or 35S.
103. The assay of claim 101 wherein said radioactive isotope comprises 93Tc, 14C, 131I, 125I, 3H, 32p or 35S,
104. Use of said antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20, 22 to 25, 27 to 31, 33 to 39, 41 or 43 to 51 for inhibiting the growth of tumor cells.
105. Use of said antibody of claim 10 for inhibiting the growth of tumor cells.
106. Use of said antibody of claim 12 for inhibiting the growth of tumor cells.
107. Use of said antibody of claim 14 for inhibiting the growth of tumor cells.
108. Use of said antibody of claim 17 for inhibiting the growth of tumor cells.
109. Use of said antibody of claim 21 for inhibiting the growth of tumor cells.
110. Use of said antibody of claim 26 for inhibiting the growth of tumor cells.
111. Use of said antibody of claim 32 for inhibiting the growth of tumor cells.
112. Use of said antibody of claim 40 for inhibiting the growth of tumor cells.
113. Use of said antibody of claim 42 for inhibiting the growth of tumor cells.
114. Use of acid antibody of claim 52 for inhibiting the growth of tumor cells.
115. Use as in claim 104 wherein said antibody is conjugated to a cytotoxic moiety.
116. Use as in any one of claims 105 to 114 wherein said antibody is conjugated to a cytotoxic moiety.
117. Use as in claim 104 wherein said tumor cells overexpress the HER2 receptor.
118. Use as in any one of claims 105 to 115 wherein said tumor cells overexpress the HER2 receptor.
119. Use as in claim 116 wherein said tumor cells overexpress the HER2 receptor.
120. Use as in claim 104 wherein said tumor cells comprise human breast, renal, gastric, or salivary gland carcinoma cells.
121. Use as in any one of claims 105 to 115, 117 or 119 wherein said tumor cells comprise human breast, renal, gastric, or salivary gland carcinoma cells.
122. Use as in claim 118 wherein said tumor cells comprise human breast, renal, gastric, or salivary gland carcinoma cells.
123. Use as in claim 118 wherein said tumor cells comprise human breast, renal, gastric, or salivary gland carcinoma cells.
124. Use as in any one of claims 120, 122 or 123 wherein said tumor cells comprise human breast carcinoma cells.
125. Use as in claim 121 wherein said tumor cells comprise human breast carcinoma cells.
126. Use of said antibody of any one of claims 1 to 9, 11, 13, 15, 16, 18 to 20, 22 to 25, 27 to 31, 33 to 39, 41 or 43 to 51 and a cytotoxic factor for inhibiting the growth of tumor cells.
127. Use of said antibody of claim 10 and a cytotoxic factor for inhibiting the growth of tumor cells.
128. Use of raid antibody of claim 12 and a cytotoxic factor for inhibiting the growth of tumor cells.
129. Use of said antibody of claim 14 and a cytotoxic factor for inhibiting the growth of tumor cells.
130. Use of said antibody of claim 17 and a cytotoxic factor for inhibiting the growth of tumor cells.
131. Use of said antibody of claim 21 and a cytotoxic factor for inhibiting the growth of tumor cells.
132. Use of said antibody of claim 26 and a cytotoxic factor for inhibiting the growth of tumor cells.
133. Use of said antibody of claim 32 and a cytotoxic factor for inhibiting the growth of tumor cells.
134. Use of said antibody of claim 40 and a cytotoxic factor for inhibiting the growth of tumor cells.
135. Use of said antibody of claim 42 and a cytotoxic factor for inhibiting the growth of tumor cells.
136. Use of raid antibody of claim 52 and a cytotoxic factor for inhibiting the growth of tumor cells.
137. Use as in claim 126 wherein said cytotoxic factor comprises TNF-.alpha., TNF-.beta., IL-1, IFN-.gamma., IL-2, 5Fu, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate or doxorubicin.
138. Use as in any one of claims 127 to 136 wherein said cytotoxic factor comprises TNF-.alpha., TNF-.beta., IL-1, IFN-.gamma., IL-2, 5Fu, vinblastine, actinomycin D, etoposide, cisplatin, methotrexate or doxorubicin.
139. Use as in claim 137 wherein said cytotoxic factor is cisplatin.
140. Use as in claim 138 wherein said cytotoxic factor is cisplatin.
141. Use as in claim 126 wherein said tumor cells overexpress the HER2 receptor.
142. Use as in any one of claims 127 to 137, 139 or 140 wherein said tumor cells overexpress the HER2 receptor.
143. Use as in claim 138 wherein said tumor cells overexpress the HER2 receptor.
144. Use as in claim 126 wherein said tumor cells are human breast, renal, gastric or salivary gland carcinoma cells.
145. Use as in any one of claims 127 to 137, 139 to 141 or 143 wheerein said tumor cells are human breast, renal, gastric or salivary gland carcinoma cells.
146. Use as in claim 138 wherein said tumor cells are human breast, renal, gastric or salivary gland carcinoma cells.
147. Use as in claim 142 wherein said tumor cells are human breast, renal, gastric or salivary gland carcinoma cells.
148. Use as in any one of claims 144, 146 or 147 wherein said tumor cells are human breast carcinoma cells.
149. Use as in claim 145 wherein said tumor cells are human breast carcinoma cells.
CA000588056A 1988-01-12 1989-01-12 Method of treating tumor cells by inhibiting growth factor receptor function Expired - Lifetime CA1341082C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14391288A 1988-01-12 1988-01-12
US07/143,912 1988-01-12
US07/147,461 1988-01-21
US14746188A 1988-01-25 1988-01-25

Publications (1)

Publication Number Publication Date
CA1341082C true CA1341082C (en) 2000-08-08

Family

ID=26841520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000588056A Expired - Lifetime CA1341082C (en) 1988-01-12 1989-01-12 Method of treating tumor cells by inhibiting growth factor receptor function

Country Status (4)

Country Link
US (7) US5677171A (en)
JP (4) JP3040121B2 (en)
CA (1) CA1341082C (en)
WO (1) WO1989006692A1 (en)

Families Citing this family (781)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US6861511B1 (en) * 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
DK0474727T3 (en) 1989-05-19 1998-01-12 Genentech Inc HER2 extracellular domain
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
EP1006194A3 (en) * 1989-08-04 2008-07-02 Triton Biosciences Inc. C-erbB-2 external domain: GP75
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
WO1991005264A1 (en) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
FR2666898A1 (en) * 1990-09-18 1992-03-20 Toledano Jacques Device and method for the rapid assay of membrane receptors or their ligands
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US7094749B1 (en) 1991-04-10 2006-08-22 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7285531B1 (en) 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5543143A (en) * 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US7754211B2 (en) * 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US6733752B1 (en) * 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1995030014A1 (en) 1994-05-02 1995-11-09 Ciba-Geigy Ag Bifunctional protein, preparation and use
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0873363B1 (en) * 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK1516628T3 (en) * 1995-07-27 2013-09-08 Genentech Inc Stable, isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
EP1695986B1 (en) * 1996-10-18 2016-12-14 Genentech, Inc. Anti-erb B2 antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CN1168495C (en) * 1997-01-15 2004-09-29 凤凰药理学公司 Modified tumor necrosis factor
DK0971959T3 (en) 1997-04-07 2006-05-15 Genentech Inc Humanized antibodies and methods for producing humanized antibodies
EP1787999B1 (en) 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US20030103984A1 (en) * 1998-05-04 2003-06-05 Heinz Kohler Fusion proteins of biologically active peptides and antibodies
DK1029046T3 (en) 1997-10-29 2009-02-02 Genentech Inc WNT-1 inducible genes
EP1027437B8 (en) 1997-10-29 2008-10-29 Genentech, Inc. Uses of the wnt-1 induced secreted polypeptide wisp-1
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) * 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1745799B1 (en) * 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20020192211A1 (en) * 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
BRPI9910332B8 (en) † 1998-05-06 2021-05-25 Genentech Inc method for purifying a polypeptide from a composition
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20040022788A1 (en) * 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
WO1999062942A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP2058334B1 (en) 1998-06-12 2012-10-31 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
EP1388734B1 (en) * 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
EP1098665B9 (en) * 1998-07-13 2003-08-13 The Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
DK1520588T3 (en) * 1998-07-13 2015-03-23 Univ Texas Use of antibodies to aminophospholipids for cancer treatment
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
ES2317702T5 (en) * 1998-08-11 2012-07-11 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodies
NO983911D0 (en) * 1998-08-26 1998-08-26 Norsk Hydro As Alginate capsules for use in the treatment of brain tumor
US20050084524A1 (en) * 1998-09-30 2005-04-21 Alza Corporation Method for potentiating activity of a chemotherapeutic drug
CA2345213A1 (en) * 1998-10-08 2000-04-13 Takeda Chemical Industries, Ltd. Agent that retards transformation of hormone-dependent cancer to non-hormone-dependent cancer
ES2543819T3 (en) * 1998-11-09 2015-08-24 Biogen Inc. Treatment of hematologic malignancies associated with circulating tumor cells using chimeric antibody directed against CD20
ATE454166T1 (en) * 1998-11-09 2010-01-15 Biogen Idec Inc TREATMENT OF PATIENTS RECEIVING A BONE MARROW TRANSPLANT OR A PERIPHERAL BLOOD STEM CELL TRANSPLANT WITH ANTI-CD20 ANTIBODIES
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7393823B1 (en) * 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
WO2000044225A1 (en) 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000069909A1 (en) 1999-05-14 2000-11-23 The United States Of America Through The Department Of Veterans Affairs Isolation and characterization of epidermal growth factor related protein
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
DE60040981D1 (en) 1999-05-14 2009-01-15 Genentech Inc TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
AU777963B2 (en) * 1999-05-19 2004-11-04 Merck Patent Gmbh Expression and export of interferon-alpha proteins as Fc fusion proteins
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
IL147017A0 (en) * 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
MXPA01013458A (en) * 1999-06-25 2002-07-30 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES.
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
PL213213B1 (en) * 1999-06-25 2013-01-31 Genentech Inc METHODS OF TREATMENT USING ANTI−ErbB ANTIBODY−MAYTANSINOID CONJUGATES
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001008636A2 (en) * 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
EP1200479B1 (en) * 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
KR20090024308A (en) 1999-08-27 2009-03-06 제넨테크, 인크. Dosages for treatment with anti-erbb2 antibodies
JP4776843B2 (en) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド Cancer composition and method using immunoconjugate and chemotherapeutic agent
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU3458401A (en) 2000-01-25 2001-08-07 Genentech Inc. Compositions and methods for treatment of cancer
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP5179689B2 (en) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Enhancing the half-life of antibody-based fusion proteins in the circulation
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
WO2001076630A1 (en) * 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for rheumatoid arthritis
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
AU5226201A (en) * 2000-04-13 2001-10-30 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
EP1935431A3 (en) * 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
CN101711868A (en) * 2000-05-19 2010-05-26 杰南技术公司 Gene detection assay for improving the likelihood of an effective response to a ErbB antibody cancer therapy
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002002143A2 (en) * 2000-06-29 2002-01-10 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
JP2004505621A (en) 2000-08-08 2004-02-26 シーワイティーワイシー　ヘルス　コーポレイション Methods for identifying viral substances in breast ducts and associated antiviral therapy
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
ATE353366T1 (en) * 2000-08-22 2007-02-15 Agensys Inc NUCLEIC ACID AND PROTEIN, CALLED 158P1D7, FOR THE TREATMENT AND DETECTION OF BLADDER CANCER AND OTHER TYPES OF CANCER
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
DE10043470B4 (en) * 2000-09-04 2006-01-19 Mpb Meltec Patent- Und Beteiligungsgesellschaft Mbh Method for the identification of cell-specific proteins
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2002060469A1 (en) * 2001-01-29 2002-08-08 Takeda Chemical Industries, Ltd. Anticancer agents
US20030190314A1 (en) * 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
BR0207649A (en) * 2001-02-27 2004-03-09 Novartis Ag A combination comprising a signal transduction inhibitor and an epothilone derivative
ES2394293T3 (en) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vaccine against cancers that are associated with the HER-2 / neu oncogene
WO2002072605A2 (en) * 2001-03-07 2002-09-19 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
IL157705A0 (en) 2001-03-14 2004-03-28 Genentech Inc Igf antagonist peptides
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2002081649A2 (en) * 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
JP4307845B2 (en) 2001-04-26 2009-08-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド Antibodies that block Cripto and uses thereof
WO2002087619A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2002088081A2 (en) * 2001-05-01 2002-11-07 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
CA2446087C (en) * 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT1392359E (en) * 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Specific binding proteins and uses thereof
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
EP1423428B2 (en) * 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
ATE477280T1 (en) * 2001-06-28 2010-08-15 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND USE THEREOF
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7662374B2 (en) * 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
ATE345812T1 (en) * 2001-09-03 2006-12-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh ANTIGEN MIMOTOPES AND VACCINES AGAINST CANCER
WO2003061559A2 (en) 2001-10-12 2003-07-31 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
GB0126531D0 (en) * 2001-11-05 2002-01-02 Glaxo Group Ltd Method
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003061571A2 (en) * 2002-01-18 2003-07-31 Chiron Corporation Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003077841A2 (en) * 2002-03-12 2003-09-25 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
ES2429112T3 (en) 2002-04-10 2013-11-13 Genentech, Inc. Anti-HER2 antibody variants
ES2545067T3 (en) * 2002-04-26 2015-09-08 Genentech, Inc. Protein purification based on non-affinity
JP4557714B2 (en) * 2002-05-10 2010-10-06 メディミューン，エルエルシー EphA2 monoclonal antibody and method of use thereof
AU2003276832A1 (en) * 2002-05-10 2004-02-25 Medimmune, Llc EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
JP4405916B2 (en) 2002-05-23 2010-01-27 トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア FAS peptidomimetics and uses thereof
SG162616A1 (en) * 2002-06-10 2010-07-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CN100418981C (en) * 2002-06-10 2008-09-17 瓦西尼斯公司 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20070073047A1 (en) * 2002-06-10 2007-03-29 Biogen Idec Ma Inc. Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
AU2003251597A1 (en) * 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
ES2377396T3 (en) * 2002-07-01 2012-03-27 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha to treat cancer such as renal cell carcinomas
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
EP1585966B8 (en) * 2002-07-15 2012-03-07 F. Hoffmann-La Roche AG Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7247303B2 (en) * 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
EP1537146B9 (en) * 2002-07-15 2011-07-06 Board Of Regents, The University Of Texas System Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
ES2368733T3 (en) * 2002-07-18 2011-11-21 Merus B.V. RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2308507B1 (en) 2002-07-19 2015-01-14 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EP1512016B1 (en) * 2002-07-22 2006-01-18 Ardana Bioscience Limited Screening method and anti-tumor drug candidate obtained therefrom
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
DE60329194D1 (en) 2002-07-25 2009-10-22 Aclara Biosciences Inc PROOF OF RECEPTOROLIGERIZATION
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20080019992A1 (en) * 2002-09-02 2008-01-24 Christoph Zielinski Antigen mimotopes and vaccine against cancerous diseases
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
AU2003265994B2 (en) 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
ES2533963T3 (en) 2002-10-10 2015-04-16 Merck Patent Gmbh Pharmaceutical compositions targeting Erb-B1 receptors
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
JP2006516117A (en) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド Treatment of non-malignant diseases or disorders using anti-ErbB2 antibodies
PT1572748E (en) * 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
SI1606409T1 (en) 2003-03-19 2011-01-31 Biogen Idec Inc Nogo receptor binding protein
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
CA2521106A1 (en) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
US8088737B2 (en) * 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
CA2521594A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US20050049176A1 (en) * 2003-04-11 2005-03-03 Kiener Peter A. EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
HUP0501182A3 (en) * 2003-04-24 2011-08-29 Incyte Corp Aza spiro alkane derivatives as inhibitors of metallproteases and pharmaceutical compositions containing them
ES2527871T3 (en) 2003-05-01 2015-02-02 Imclone Llc Fully human antibodies directed against human insulin-like growth factor 1 receptor
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CA2525969A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
JP2007500251A (en) * 2003-06-13 2007-01-11 ベクトン・ディキンソン・アンド・カンパニー Improved intradermal delivery of biologically active agents
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US20040254108A1 (en) * 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
KR101581040B1 (en) 2003-06-27 2015-12-30 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
AU2004265253B2 (en) 2003-07-28 2011-09-01 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
JP2007501011A (en) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド Binding polypeptide having restriction diversity sequence
US7674460B2 (en) * 2003-08-01 2010-03-09 A&G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005019470A2 (en) * 2003-08-11 2005-03-03 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
CA2543888C (en) 2003-11-06 2016-01-19 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20050208058A1 (en) * 2003-11-21 2005-09-22 Doxsey Stephen J Compositions and methods for modulating cell division
CA2548180C (en) * 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
WO2005058232A2 (en) * 2003-12-11 2005-06-30 Tercica, Inc. Methods and compositions for the treatment of prolactin-receptor related disorders
DE602004013372T2 (en) * 2003-12-30 2009-07-02 Merck Patent Gmbh IL-7 FUSION PROTEINS WITH ANTIBODY PORTIONS, THEIR PREPARATION AND THEIR USE
DK1699821T3 (en) * 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2005065418A2 (en) * 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
JP5912211B2 (en) 2004-01-20 2016-04-27 メルス ビー．ヴィー． Mixture of binding proteins
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
EP1708752B1 (en) * 2004-01-27 2012-02-22 University Of Southern California Polymer-bound antibody cancer therapeutic agent
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
US7598350B2 (en) * 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
ATE540696T1 (en) * 2004-04-08 2012-01-15 David B Agus ERBB2 ANTAGONISTS FOR TUMOR PAIN THERAPY
WO2005120557A2 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
CA2569202A1 (en) * 2004-05-28 2005-12-15 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CA2570884C (en) 2004-06-16 2016-04-19 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
KR20070043795A (en) * 2004-07-20 2007-04-25 쉐링 코포레이션 Induction of apoptosis in toll-like receptor expressing tumor cells
US20060018829A1 (en) * 2004-07-22 2006-01-26 Smith Henry J Cellular receptors utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment
UA90480C2 (en) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. HER2 antibody composition exhibiting anticancer activity
NZ552713A (en) 2004-07-23 2010-06-25 Genentech Inc Crystallization of anti-VEGF antibodies or fragments thereof using divalent cations
US7659374B2 (en) * 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (en) 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
DK1804836T3 (en) 2004-09-24 2011-01-24 Beth Israel Hospital Methods for diagnosing and treating pregnancy complications
KR20070073886A (en) * 2004-10-05 2007-07-10 제넨테크, 인크. Therapeutic agents with decreased toxicity
EP1807106A2 (en) * 2004-10-05 2007-07-18 Oregon Health and Science University Compositions and methods for treating disease
EP1797431B1 (en) * 2004-10-06 2011-01-26 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
KR101027427B1 (en) 2004-11-12 2011-04-11 젠코어 인코포레이티드 Fc VARIANTS WITH INCREASED BINDING TO FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2715776T3 (en) 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatins that have an aminobenzoic acid unit at the N-terminus
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
WO2006078307A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
RU2393874C2 (en) * 2005-02-01 2010-07-10 Рисерч Дивелопмент Фаундейшн Polypeptides of directed action
EP1841794B1 (en) * 2005-02-02 2013-11-20 MacroGenics West, Inc. Adam-9 modulators
DE602006021142D1 (en) 2005-02-03 2011-05-19 Gen Hospital Corp METHOD FOR THE TREATMENT OF GEFITINIB-RESISTANT CANCER
RU2007133660A (en) * 2005-02-09 2009-03-20 Дженентек, Инк. (Us) HER2 SHADDING INHIBITION BY MATRIX METALLOPROTEINASE ANTAGONISTS
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US20060188509A1 (en) 2005-02-23 2006-08-24 Genentech, Inc. Extending time to disease progression or survival in cancer patients
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
BRPI0610026A2 (en) * 2005-04-22 2010-05-18 Alza Corp immunoliposome composition for targeting a her2 cell receptor
AU2006298519A1 (en) * 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
AU2006261342B2 (en) * 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
PL2100618T3 (en) 2005-06-17 2014-07-31 Imclone Llc An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
EP2478917A1 (en) 2005-07-08 2012-07-25 Biogen Idec MA Inc. SP35 antibodies and uses thereof
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
EP2500356A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2623293A1 (en) * 2005-09-20 2007-03-29 Shimon Benita Nanoparticles for targeted delivery of active agents
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
RU2451524C2 (en) 2005-11-04 2012-05-27 Вайет Anti-tumour combinations mtor inhibitors, herceptin and/or hki-272
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
ATE492651T1 (en) * 2005-11-10 2011-01-15 Bristol Myers Squibb Pharma Co MOESIN, CAVEOLIN 1 AND YES-ASSOCIATED PROTEIN 1 AS PREDICTIVE MARKERS OF RESPONSE TO DASATINIB IN BREAST CANCER
RU2470941C2 (en) * 2005-12-02 2012-12-27 Дженентек, Инк. Binding polypeptides and use thereof
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CN101351475B (en) * 2005-12-30 2013-05-15 默克专利有限公司 Interleukin-12p40 variants with improved stability
EP1966245B1 (en) 2005-12-30 2011-05-18 Merck Patent GmbH Anti-cd19 antibodies with reduced immunogenicity
BRPI0620888A2 (en) * 2006-01-04 2011-11-29 Merck Patent Gmbh combination therapy using anti-egfr and anti-her2 antibodies
EP1984011A4 (en) 2006-02-03 2010-08-18 Imclone Llc Igf-ir antagonists as adjuvants for treatment of prostate cancer
DE102006011507A1 (en) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Active substance-loaded nanoparticles based on hydrophilic proteins
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
ES2718952T3 (en) 2006-06-07 2019-07-05 Bioalliance Cv Antibodies that recognize an epitope that contains carbohydrates on CD-43 and CEA expressed in cancer cells and methods that use them
AU2007261247A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-C35 antibodies for treating cancer
EP2046385B1 (en) 2006-07-03 2015-03-25 Charles David Adair Composition for modulating the expression of cell adhesion molecules
PT2511301T (en) 2006-08-04 2018-03-08 Medimmune Ltd Human antibodies to erbb 2
NZ574580A (en) 2006-08-21 2011-12-22 Hoffmann La Roche Her2 tumor therapy with an anti-vegf antibody
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700579A1 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
MX2009003660A (en) * 2006-10-06 2009-04-22 Takeda Pharmaceutical Combination drug.
CL2007003411A1 (en) 2006-11-28 2008-07-04 Centelion PROTEIN FUSION THAT CONSISTS IN AN FC REGION OF AN IMMUNOGLOBULIN WITH A FRAGMENT OR SOLUBLE DOMAIN OF A RECEIVER FOR FGF; POLINUCLEOTIDO THAT CODIFIES AND VECTOR AND CELL THAT UNDERSTAND IT; PHARMACEUTICAL COMPOSITION INCLUDING PROTEIN FU
AU2007333735A1 (en) 2006-12-19 2008-06-26 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
MX338185B (en) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Use of anti-egfr antibodies in treatment of egfr mutant mediated disease.
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
US9155753B2 (en) 2007-03-09 2015-10-13 Geron Corporation Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
JP5618549B2 (en) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Method of treatment using EGFR antibody and SRC inhibitor and related preparation
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009011228A (en) * 2007-04-19 2009-11-02 Wellstat Biologics Corp Detection her-2/neu protein from non-isolated circulating cancer cells and treatment.
US20090252729A1 (en) * 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
JP5064558B2 (en) 2007-06-01 2012-10-31 エフ．ホフマン−ラ ロシュ アーゲー Immunoglobulin purification
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2583377T3 (en) 2007-06-08 2016-09-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
ES2528922T3 (en) 2007-07-16 2015-02-13 Genentech, Inc. Humanized and immunoconjugate anti-CD79b antibodies and methods of use
DK2474557T3 (en) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
EP2192919A1 (en) * 2007-08-24 2010-06-09 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
CA2699944C (en) 2007-09-21 2017-11-14 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101889025B (en) 2007-10-30 2013-11-13 健泰科生物技术公司 Antibody purification by cation exchange chromatography
MX2010005115A (en) 2007-11-08 2010-05-27 Genentech Inc Anti-factor b antibodies and their uses.
AU2008325107B2 (en) * 2007-11-08 2015-04-23 Biogen Ma Inc. Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
AR069393A1 (en) * 2007-11-21 2010-01-20 Imclone Systems Inc INHIBITION OF THE RECEIVER FOR MACROFAGO STIMULATING PROTEIN (RON) AND METHODS FOR THE TREATMENT OF THE SAME
WO2009070772A1 (en) * 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
US7982017B2 (en) 2007-12-18 2011-07-19 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US8637026B2 (en) * 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
EP2808343B8 (en) 2007-12-26 2020-01-15 Xencor, Inc. Fc variants with altered binding to FcRn
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
SG189769A1 (en) 2008-01-03 2013-05-31 Scripps Research Inst Antibody targeting through a modular recognition domain
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
AU2009210636B2 (en) 2008-01-31 2014-08-28 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP2262531A1 (en) * 2008-03-08 2010-12-22 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
DK2254571T3 (en) 2008-03-18 2015-09-28 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and the chemotherapeutic agents and methods of using
DK2842575T3 (en) 2008-03-18 2017-11-27 Seattle Genetics Inc Auristatin drug linker conjugates
MX2010011955A (en) 2008-04-29 2011-01-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
ES2342646B1 (en) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron METHOD OF DIAGNOSIS OF CANCERES THAT EXPRESS THE RECEIVER HER-2 OR ITS TRUNCATED VARIANTS.
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
PT2310011E (en) 2008-06-17 2013-10-07 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
ES2687259T5 (en) 2008-06-25 2022-10-14 Novartis Ag Stable and soluble antibodies that inhibit TNF
HUE032894T2 (en) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies inhibiting vegf
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
JP2011527572A (en) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Composition comprising a LINGO antibody or fragment
PT2326329T (en) 2008-08-04 2017-02-14 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
PL2328923T3 (en) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Cd133 epitopes
SG195558A1 (en) 2008-10-14 2013-12-30 Genentech Inc Immunoglobulin variants and uses thereof
JP2012507299A (en) * 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド LIGHT target molecule and use thereof
CA2744158A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Anti-angiogenesis therapy for the treatment of breast cancer
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
CA2745111A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
CA2745271A1 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
KR20140020368A (en) 2008-12-23 2014-02-18 제넨테크, 인크. Methods and compositions for diagnostic use in cancer patients
RU2636046C2 (en) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Modified antibodies composition, methods of production and application
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP2398494A4 (en) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and methods of use thereof
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
TW201438739A (en) 2009-03-20 2014-10-16 Genentech Inc Anti-HER antibodies
PT3000467T (en) 2009-04-06 2023-03-30 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
MX2011010169A (en) 2009-04-07 2011-10-11 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies.
CA2757531A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
KR20120030383A (en) * 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 Antibody fusion proteins with modified fcrn binding sites
US8383768B2 (en) 2009-05-07 2013-02-26 Immunocellular Therapeutics, Ltd. CD133 epitopes
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
RU2012101999A (en) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи Fc RECOMBINED SITES FOR SITE-SPECIFIC CONJUGATION
WO2011003780A1 (en) 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
CA2766403A1 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG178419A1 (en) 2009-08-15 2012-04-27 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CA2772628A1 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
SG179070A1 (en) 2009-09-11 2012-04-27 Genentech Inc Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
AU2010297344A1 (en) 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011039274A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Multistep final filtration
TR201804897T4 (en) 2009-10-07 2018-06-21 Macrogenics Inc POLYPEPTIDES CONTAINING FC REGION WITH ADVANCED EFFECTOR FUNCTION DUE TO CHANGES OF FUCOSILATION SIZE AND METHODS FOR THEIR USE
AR078651A1 (en) 2009-10-15 2011-11-23 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
WO2011069074A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
PL2330131T3 (en) 2009-12-07 2015-05-29 Fundacio Privada Inst Catalana De Recerca I Estudis Avancants Antibodies against HER2 truncated variant CTF-611
PL2515941T3 (en) 2009-12-21 2020-04-30 F. Hoffmann-La Roche Ag Pharmaceutical formulation of bevacizumab
AU2010336485B2 (en) 2009-12-23 2015-03-26 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
ES2519348T3 (en) 2010-02-18 2014-11-06 Genentech, Inc. Neurregulin antagonists and their use in cancer treatment
KR20180028561A (en) 2010-02-23 2018-03-16 제넨테크, 인크. Anti-angiogenesis therapy for the treatment of ovarian cancer
SG10201501342UA (en) 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
CA2794745A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies aganist her2
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
CA2803900A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
BR112013000340A2 (en) 2010-07-09 2016-05-31 Genentech Inc isolated antibody that binds neuropillin-1 (nrp1), isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate and method of detecting nrp1 in a biological sample
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2596362A1 (en) 2010-07-19 2013-05-29 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010548A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CN103261225A (en) 2010-07-23 2013-08-21 波士顿大学董事会 Anti-desupr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
CN105585630B (en) 2010-07-29 2020-09-15 Xencor公司 Antibodies with modified isoelectric points
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9464136B2 (en) 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
KR20130139884A (en) 2010-08-26 2013-12-23 애브비 인코포레이티드 Dual variable domain immunoglobulins and uses thereof
WO2012032043A1 (en) 2010-09-07 2012-03-15 Areva Med Llc 212 pb imaging
AR083495A1 (en) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit STABLE AND SOLUBLE ANTIBODIES
NZ610538A (en) 2010-11-15 2015-02-27 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5621052B2 (en) 2010-12-21 2014-11-05 エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Chromatographic equipment characterization
RU2627171C2 (en) 2010-12-21 2017-08-03 Эббви Инк. Il-1 alpha and beta bispecific immunoglobulins with double variable domains and their application
US20140162317A1 (en) 2010-12-21 2014-06-12 Roberto Falkenstein Isoform entriched antibody preparation and method for obtaining it
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2822481A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
MY163539A (en) 2011-03-29 2017-09-15 Roche Glycart Ag Antibody fc variants
EP3636279B1 (en) 2011-04-01 2023-09-13 ImmunoGen, Inc. Methods for increasing efficacy of folr1 cancer therapy
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
ES2701929T3 (en) 2011-05-19 2019-02-26 Laboratory Corp America Holdings Methods to determine the probability of survival and to predict the probability of metastasis in cancer
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CN103747807B (en) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97 antibody conjugates and using method
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
CA2842971C (en) 2011-08-05 2019-11-12 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
PT2739649T (en) 2011-08-05 2018-01-03 Bioasis Technologies Inc P97 fragments with transfer activity
MX2014001736A (en) 2011-08-17 2014-03-31 Genentech Inc Inhibition of angiogenesis in refractory tumors.
KR20140057326A (en) 2011-08-17 2014-05-12 제넨테크, 인크. Neuregulin antibodies and uses thereof
EP3611187A1 (en) 2011-10-10 2020-02-19 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN109908341B (en) 2011-10-14 2023-06-27 霍夫曼-拉罗奇有限公司 Use of the HER2 dimerization inhibitor pertuzumab and articles of manufacture comprising the HER2 dimerization inhibitor pertuzumab
US8999331B2 (en) 2011-10-24 2015-04-07 Abbvie Inc. Immunobinders directed against sclerostin
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
JP6149042B2 (en) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション HER3 antibody and use thereof
RU2014126098A (en) 2011-11-30 2016-01-27 Дженентек, Инк. Mutations of ErbB3 in Cancer
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
SG11201402737SA (en) 2011-12-05 2014-06-27 Hoffmann La Roche Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
LT2825558T (en) 2012-03-13 2019-08-12 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
EA202090591A3 (en) 2012-04-20 2020-12-30 Мерюс Н.В. METHODS AND MEANS FOR OBTAINING Ig-LIKE MOLECULES
ES2431914B2 (en) * 2012-04-27 2014-07-24 Universidad De Cádiz ANTI-HER2 human monoclonal antibody
JP2015518829A (en) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-2 antagonist for treatment of conditions involving motor neurons
SG10201603055WA (en) 2012-05-31 2016-05-30 Genentech Inc Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CA2871385A1 (en) 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
AR091755A1 (en) 2012-07-12 2015-02-25 Abbvie Inc PROTEINS OF UNION TO IL-1
CA2874554C (en) 2012-07-13 2019-12-03 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
BR112015002681A2 (en) 2012-08-07 2018-08-28 Genentech Inc method to treat a patient and kit
UA118251C2 (en) 2012-08-23 2018-12-26 Ейдженсіс, Інк. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
EP3584255B1 (en) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
CN104755498B (en) 2012-08-31 2019-06-18 伊缪诺金公司 For detecting the diagnostic assay and kit of folacin receptor 1
US10093740B2 (en) 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
WO2020074469A1 (en) 2018-10-08 2020-04-16 Universität Zürich Her2-binding tetrameric polypeptides
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
WO2014066590A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
KR20180008921A (en) 2012-11-01 2018-01-24 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
RU2020139283A (en) 2012-11-01 2020-12-10 Эббви Инк. STABLE COMPOSITION OF IMMUNOGLOBULIN PROTEIN WITH DOUBLE VARIABLE DOMAINS
EP2926142B2 (en) 2012-11-30 2022-07-06 F. Hoffmann-La Roche AG Identification of patients in need of pd-l1 inhibitor cotherapy
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
LT2943511T (en) 2013-01-14 2019-11-11 Xencor Inc Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
ES2774549T3 (en) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragments of P97 and uses thereof
SG10201913932VA (en) 2013-03-13 2020-03-30 Genentech Inc Antibody formulations
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EA038918B1 (en) 2013-03-15 2021-11-09 Зинджения, Инк. Peptide binding an epidermal growth factor receptor, multispecific complexes comprising peptide and antibodies and use thereof
AU2014233528B2 (en) 2013-03-15 2019-02-28 Abbvie Biotherapeutics Inc. Fc variants
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AU2014240063B2 (en) 2013-03-15 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2981828A1 (en) 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
RU2019115089A (en) 2013-04-16 2019-06-11 Дженентек, Инк. VARIANTS OF PERTUSUMAB AND THEIR ANALYTICAL CHARACTERISTICS
WO2014170032A1 (en) 2013-04-19 2014-10-23 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
DK3677591T3 (en) 2013-04-29 2023-03-20 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
JP2016520586A (en) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド Bispecific HER2 and HER3 antigen binding constructs
BR112015029145A2 (en) 2013-05-23 2017-09-19 Glaxosmithkline Ip No 2 Ltd USES OF A FIBROBLAST GROWTH FACTOR 1 (FGFR1) RECEPTOR EXTRACELLULAR DOMAIN (ECD) AND PATIENT IDENTIFICATION METHODS
ES2736326T3 (en) 2013-05-31 2019-12-27 Zymeworks Inc Heteromultimers with reduced or silenced effector function
ES2865473T3 (en) 2013-07-10 2021-10-15 Sutro Biopharma Inc Antibodies Comprising Multiple Site-Specific Unnatural Amino Acid Residues, Methods for Their Preparation, and Methods of Use
WO2015006736A2 (en) 2013-07-11 2015-01-15 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
US9914775B2 (en) 2013-08-21 2018-03-13 The Board Of Regents Of The University Of Texas System Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (Cx43) hemichannels
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CN113150145A (en) 2013-08-30 2021-07-23 伊缪诺金公司 Antibodies and assays for detecting folate receptor 1
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104628846B (en) 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 Method for purifying recombinant protein
US10669328B2 (en) 2013-11-12 2020-06-02 Ogd2 Pharma Human IgG1 derived antibody with pro-apoptotic activity
SG10201809385RA (en) 2013-12-17 2018-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
EP4212552A1 (en) 2014-01-31 2023-07-19 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
BR112016017933A2 (en) 2014-02-03 2017-10-10 Bioasis Technologies Inc ? p97 fusion proteins?
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
KR20150097304A (en) 2014-02-18 2015-08-26 삼성전자주식회사 Anti-EGFR/Anti-HER2 Bispecific Antibodies With Anti-EGFR DARPins
WO2015126729A1 (en) 2014-02-19 2015-08-27 Bioasis Technologies, Inc. P97-ids fusion proteins
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104650233A (en) * 2014-03-11 2015-05-27 南京任诺药业有限公司 ADC-drug-modified antibody IgG1-CH-K330C for establishing radioactive isotope coupling labelling
KR20160137599A (en) 2014-03-24 2016-11-30 제넨테크, 인크. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
UA119167C2 (en) 2014-03-28 2019-05-10 Зенкор, Інк. Bispecific antibodies that bind to cd38 and cd3
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
ES2754348T3 (en) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugate of (anti-HER2 antibody) -pharmaceutical
CN106232139A (en) 2014-04-11 2016-12-14 免疫医疗有限责任公司 Bispecific HER2 antibody
WO2015159254A1 (en) 2014-04-16 2015-10-22 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
EP3134541B1 (en) 2014-04-21 2020-08-19 Natera, Inc. Detecting copy number variations (cnv) of chromosomal segments in cancer
RU2725093C2 (en) 2014-04-25 2020-06-29 Дженентек, Инк. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CN114181312A (en) 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 Galactose engineered immunoglobulin 1 antibodies
BR112017004631A2 (en) 2014-09-12 2018-01-30 Genentech, Inc. antibody, nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, methods of treatment, cell proliferation inhibition and human her2 detection and method for cancer detection
EP3388449A3 (en) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
MX2017003121A (en) 2014-09-15 2017-08-02 Genentech Inc Antibody formulations.
WO2016044396A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
SI3262071T1 (en) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
EA201791029A1 (en) 2014-11-10 2017-12-29 Дженентек, Инк. ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
IL252480B2 (en) 2014-11-26 2023-12-01 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016088376A1 (en) * 2014-12-03 2016-06-09 株式会社アネロファーマ・サイエンス Coexpression plasmid
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CA2971517A1 (en) 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3237639A2 (en) 2014-12-23 2017-11-01 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
KR102462811B1 (en) 2015-04-27 2022-11-04 에이비온 주식회사 Dendron conjugated antibody and use thereof
CN107849096B (en) 2015-05-30 2022-05-24 分子模板公司 Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising them
US11406715B2 (en) 2015-05-30 2022-08-09 Genentech, Inc. Methods of treating HER2-positive metastatic breast cancer
AU2016274584A1 (en) 2015-06-08 2018-01-04 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
TW201709929A (en) 2015-06-12 2017-03-16 宏觀基因股份有限公司 Combination therapy for the treatment of cancer
AR104987A1 (en) 2015-06-15 2017-08-30 Genentech Inc ANTIBODY-DRUG IMMUNOCUJADOS UNITED BY NON-PEPTIDIC LINKERS
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CN114507289A (en) 2015-06-16 2022-05-17 豪夫迈·罗氏有限公司 Humanized and affinity matured antibodies to FcRH5 and methods of use
WO2017002776A1 (en) 2015-06-29 2017-01-05 第一三共株式会社 Method for selectively manufacturing antibody-drug conjugate
PT3319995T (en) 2015-07-07 2019-06-14 H Hoffnabb La Roche Ag Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
EP4129327A1 (en) 2015-08-28 2023-02-08 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
CA2994888A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
SI3368578T1 (en) 2015-10-30 2021-08-31 F. Hoffmann-La Roche Ag Anti-htra1 antibodies and methods of use thereof
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (en) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 anti-ErbB 2 antibody-drug conjugate, and composition, preparation method and application thereof
ES2861449T3 (en) 2015-12-02 2021-10-06 Stcube & Co Inc Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
CN109071642B (en) 2016-02-26 2022-08-09 德克萨斯大学体系董事会 Connexin (Cx)43 hemichannel binding antibodies and uses thereof
GEP20217232B (en) 2016-03-14 2021-03-25 I Oslo Universitetet Engineered immunoglobulins with altered fcrn binding
CA3017608A1 (en) 2016-03-29 2017-10-05 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
EP3443350B1 (en) 2016-04-15 2020-12-09 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
SG11201809316XA (en) 2016-04-28 2018-11-29 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
MA45255A (en) 2016-06-14 2019-04-17 Xencor Inc BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
CN109890982B (en) 2016-07-08 2023-07-07 基因泰克公司 Method for diagnosing and treating cancer by expression status and mutation status of NRF2 and target genes downstream thereof
CA3030926A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
CN107446045A (en) 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 A kind of anti-HER2 antibody, its pharmaceutical composition and purposes
US10377833B2 (en) 2016-07-22 2019-08-13 Beijing Mabworks Biotech Co., Ltd. Bispecific anti-HER2 antibody
KR20180013587A (en) 2016-07-29 2018-02-07 서울대학교산학협력단 Compositions for treating or sensitizing interferon beta-resistant cancer comprising cFLIP siRNA
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3036941C (en) 2016-10-07 2023-02-21 Daiichi Sankyo Company, Limited Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
CN109983027A (en) 2016-10-20 2019-07-05 细胞基因公司 Based on CEREBLON can heterodimerization Chimeric antigen receptor
KR20190073600A (en) 2016-10-21 2019-06-26 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 Prognostic method and kits useful in said method
US20180134803A1 (en) 2016-11-04 2018-05-17 Genentech, Inc. Treatment of her2-positive breast cancer
CN109923128A (en) 2016-11-15 2019-06-21 基因泰克公司 Administration for being treated with anti-CD20/ AntiCD3 McAb bispecific antibody
JPWO2018110515A1 (en) 2016-12-12 2019-10-24 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
MX2019007801A (en) 2016-12-28 2019-10-30 Genentech Inc Treatment of advanced her2 expressing cancer.
TWI780104B (en) 2017-01-17 2022-10-11 日商第一三共股份有限公司 Anti gpr20 antibodies and anti gpr20 antibody-drug conjugates, as well as manufacturing method and use thereof
CN115089704A (en) 2017-01-17 2022-09-23 基因泰克公司 Subcutaneous HER2 antibody formulation
FI3582806T3 (en) 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
AU2018228873A1 (en) 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR20230144110A (en) 2017-03-02 2023-10-13 제넨테크, 인크. Adjuvant treatment of her2-positive breast cancer
KR20190140952A (en) 2017-04-24 2019-12-20 제넨테크, 인크. ERBB2 / HER2 mutations in transmembrane and proximal membrane domains
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
TWI794230B (en) 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20200015602A (en) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Antibodies and molecules immunospecifically binding to BTN1A1 and therapeutic uses thereof
KR20200026209A (en) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
CA3067603A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
CN117838880A (en) 2017-08-31 2024-04-09 第一三共株式会社 New method for preparing antibody-drug conjugate
BR112020003646A2 (en) 2017-08-31 2020-09-01 Daiichi Sankyo Company, Limited crystals, methods for producing crystals and an antibody-drug conjugate, and, salt.
US11464784B2 (en) 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CR20200391A (en) 2018-02-08 2020-10-19 Genentech Inc Bispecific antigen-binding molecules and methods of use
TW202003561A (en) 2018-03-13 2020-01-16 瑞士商赫孚孟拉羅股份公司 Combination therapy with targeted 4-1BB (CD137) agonists
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
MX2020010732A (en) 2018-04-13 2020-11-09 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl.
JP7323200B2 (en) 2018-04-17 2023-08-08 モレキュラー テンプレーツ，インク． HER2 Targeting Molecules Containing Deimmunized Shiga Toxin A Subunit Scaffolds
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
US20210221910A1 (en) 2018-05-18 2021-07-22 Glycotope Gmbh Anti-muc1 antibody
EP3584258A1 (en) * 2018-06-19 2019-12-25 IEO - Istituto Europeo di Oncologia Srl Antibodies anti tumor associated antigens and method for obtaining them
WO2020028909A1 (en) 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
CA3114179A1 (en) 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
KR20210069641A (en) 2018-10-03 2021-06-11 젠코어 인코포레이티드 IL-12 heterodimeric Fc-fusion protein
CN113329769A (en) 2018-10-11 2021-08-31 斯克里普斯研究学院 Antibody compounds with reactive arginine and related antibody drug conjugates
EP3856774B1 (en) 2018-10-15 2022-11-02 F. Hoffmann-La Roche AG Methods of treating residual breast cancer with trastuzumab emtansine
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
CN113677403A (en) 2019-04-12 2021-11-19 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules comprising lipocalin muteins
JP2022536490A (en) 2019-06-10 2022-08-17 ストロ バイオファーマ インコーポレーテッド 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
MX2021015221A (en) 2019-06-13 2022-03-17 Bolt Biotherapeutics Inc Aminobenzazepine compounds, immunoconjugates, and uses thereof.
US20220259202A1 (en) 2019-06-17 2022-08-18 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
JP2022546110A (en) 2019-09-03 2022-11-02 ボルト バイオセラピューティクス、インコーポレーテッド Aminoquinoline compounds, immunoconjugates, and uses thereof
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
CA3152601A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
MX2022004875A (en) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Thienoazepine immunoconjugates, and uses thereof.
EP4058024A1 (en) 2019-11-15 2022-09-21 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP3889183A1 (en) 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
JP2023520515A (en) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド Therapeutic and diagnostic methods for cancer
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
TW202216769A (en) 2020-06-23 2022-05-01 瑞士商赫孚孟拉羅股份公司 Agonistic cd28 antigen binding molecules targeting her2
JP2023537940A (en) 2020-08-13 2023-09-06 ボルト バイオセラピューティクス、インコーポレーテッド Pyrazoloazepine immunoconjugates and uses thereof
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US20220152030A1 (en) 2020-11-13 2022-05-19 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
IL303502A (en) 2020-12-11 2023-08-01 Genentech Inc Combination therapies for treatment of her2 cancer
JP2023552792A (en) 2020-12-11 2023-12-19 ボルト バイオセラピューティクス、インコーポレーテッド Anti-HER2 immune complexes and uses thereof
CN116897054A (en) 2020-12-11 2023-10-17 博尔特生物治疗药物有限公司 anti-HER 2 immunoconjugates and uses thereof
CN116745324A (en) 2021-01-27 2023-09-12 信达生物制药(苏州)有限公司 Single domain antibodies against CD16A and uses thereof
JP2024511319A (en) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
TW202304520A (en) 2021-03-26 2023-02-01 美商博特生物治療公司 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
EP4313161A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
AU2022302170A1 (en) 2021-07-02 2023-12-21 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023014597A1 (en) 2021-08-02 2023-02-09 Natera, Inc. Methods for detecting neoplasm in pregnant women
GB202112907D0 (en) 2021-09-10 2021-10-27 Res & Innovation Uk Methods of biomolecule display
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
EP4180061A1 (en) 2021-11-10 2023-05-17 Nerviano Medical Sciences S.r.l. Anthracycline derivative linker reagents, antibody-drug conjugates and methods
WO2023164487A1 (en) 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
WO2023166098A1 (en) 2022-03-02 2023-09-07 Biomunex Pharmaceuticals Bispecific antibodies binding to her-3 and to either her-2 or egfr
US20240091365A1 (en) 2022-06-27 2024-03-21 Sutro Biopharma, Inc. Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2024015229A1 (en) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Protease/enzyme cleavable linker-payloads and protein conjugates

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
EP0118365B1 (en) * 1983-03-04 1990-08-29 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4906646A (en) * 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US5108934A (en) * 1983-11-30 1992-04-28 Kabushiki Kaisha Toshiba Quantitative immunoassay utilizing liposomes
AU3934085A (en) * 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS60243027A (en) * 1984-05-17 1985-12-03 Ajinomoto Co Inc Antibody
US4957735A (en) * 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
JPH076982B2 (en) * 1985-11-06 1995-01-30 株式会社ニチレイ Body
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3752219T2 (en) * 1986-05-19 1999-02-18 Seiko Epson Corp Liquid crystal display device
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
CA1341191C (en) * 1988-04-18 2001-02-27 Robert Allan Weinberg Detection of neu gene expression and products
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
DK0474727T3 (en) * 1989-05-19 1998-01-12 Genentech Inc HER2 extracellular domain
EP1006194A3 (en) * 1989-08-04 2008-07-02 Triton Biosciences Inc. C-erbB-2 external domain: GP75
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
PT616812E (en) * 1993-03-24 2000-04-28 Berlex Biosciences COMBINATION OF ANTI-HORMONAL COMPOUNDS AND LIGACATION MOLECULES IN CANCER TREATMENT
WO1994022478A1 (en) * 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
EP0873363B1 (en) * 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
WO1998031394A2 (en) 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
US5720954A (en) 1998-02-24
US6387371B1 (en) 2002-05-14
JP2007186523A (en) 2007-07-26
JP3040121B2 (en) 2000-05-08
JPH03502885A (en) 1991-07-04
US5772997A (en) 1998-06-30
JPH11255666A (en) 1999-09-21
US5677171A (en) 1997-10-14
US6165464A (en) 2000-12-26
WO1989006692A1 (en) 1989-07-27
JPH11335297A (en) 1999-12-07
US5770195A (en) 1998-06-23
US6399063B1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
CA1341082C (en) Method of treating tumor cells by inhibiting growth factor receptor function
US5725856A (en) Monoclonal antibodies directed to the HER2 receptor
US20020192211A1 (en) Method of treating tumor cells by inhibiting growth factor receptor function
KR101960509B1 (en) Antibodies specific for claudin 6 (cldn6)
Yu et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14. 18 in patients with refractory neuroblastoma and osteosarcoma.
EP0578774B1 (en) Monoclonal antibodies to stem cell factor receptors
US7090844B2 (en) Use of antibodies against the MUC18 antigen
JP3600617B2 (en) Monoclonal antibody specific for human epidermal growth factor receptor and therapeutic agent using the same
US7067131B2 (en) Methods for using anti-MUC18 antibodies
KR101683884B1 (en) Anti-epcam antibody and uses thereof
WO1994009150A1 (en) Monoclonal antibodies to prostate cells
US20030082188A1 (en) Treatment of prostate cancer by inhibitors of NCAM2
JP2001521520A (en) Anti-α-low v ▼ β-low 3 ▼ Integrin antibody antagonist
US20200255536A1 (en) Target for b-cell disorders
PL171920B1 (en) Method of obtaining a novel immunoglobulin polypeptide capable to inhibit pdgf-r
JPH05500600A (en) Anti-idiotype antibodies and their use for inducing immune responses against glycosphingolipids
JP2000509015A (en) Use of antibodies against CD48 for the treatment of T and B cell lymphomas and leukemias
US6440733B1 (en) Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
US5523085A (en) Monoclonal antibody in destruction of small cell lung carcinoma
Fleenor Characterization of three monoclonal antibodies directed against a bovine cerebral cortex cell surface sialoglycopeptide

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20170808